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 Apoptosis is a critical regulator of brain development and dysregulation of 
apoptosis is a hallmark of many brain cancers. In post-natal cerebellar development 
rapidly dividing progenitor cells give rise to the largest population of neurons in the adult 
brain. This highly proliferative process requires strict growth control via apoptosis to 
prevent medulloblastoma (MB), the most common malignant brain tumor in children. 
Our previous studies highlight a conserved apoptotic priming mechanism in cerebellar 
granule neural progenitors (CGNPs) and medulloblastoma cells that allows for rapid 
induction of cell death after a cytotoxic stimulus.   
We have shown apoptotic priming is mediated by an activated form of the pro-
apoptotic gate-keeper BAX, that is harbored at the mitochondrial outer membrane.  BAX 
is preferentially bound to the anti-apoptotic homolog BCL-xL preventing mitochondrial 
outer membrane permeabilization (MOMP) and subsequent Cytochrome C (CytoC) 
release.  This dissertation tests the hypothesis that disruption of BCL-xL precipitates 
spontaneous apoptosis in CGNPs and MB cells, a unique molecular mechanism that 
could be exploited for the treatment of medulloblastoma.  
In Chapter 2 of this dissertation I show that conditional deletion of Bcl2l1, the 
locus that encodes Bcl-xL, causes substantial growth failure of the developing 
cerebellum due to increased apoptosis in both proliferating CGNPS and cells that have 
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recently exited the cell cycle, and prolongs the period of Sonic hedgehog (SHH) driven 
post-natal proliferation. These phenomena are BAX dependent, as co-deletion of Bcl2l1 
and Bax reverses the cerebellar hypoplasia, heightened rate of apoptosis and 
lengthened duration of proliferation seen with deletion of Bcl2l1 alone. Additionally, I 
show that the anti-apoptotic homolog MCL-1 is expressed in CGNPs across the cell 
cycle but is only required for sustaining proliferating CGNPs in the absence of BCL-xL, 
demonstrating a hierarchical need for anti-apoptotic factors throughout distinct 
developmental stages in the cerebellum. These findings contrast the canonical narrative 
in which MCL-1 is thought to be vital for survival of neural precursor cells (NPCs) while 
post-mitotic neurons rely mostly on expression of BCL-xL and provide a more nuanced 
understanding of apoptotic regulation in the developing nervous system. Furthermore, 
they suggest that the apoptotic mechanisms present in embryonic brain growth function 
differently in post-natal proliferation of the cerebellum.  
CGNPs are the cells of origin for SHH-subtype medulloblastoma, and Chapter 3 
of this dissertation examines the hypothesis that the mechanisms governing apoptosis 
in the developing cerebellum also operate in medulloblastoma and can be directly 
targeted as a potential treatment.  Specifically, I show that Bcl2l1 deletion in our mouse 
model of SHH-driven medulloblastoma induces widespread apoptosis resulting in focal 
areas of tumor necrosis and lengthens the life-span of tumor bearing mice. Deletion of 
Bcl-xL in MB tumors, like CGNPs, elevates levels of apoptosis in both proliferating MB 
cells and MB cells that have recently exited the cell cycle, with the latter being most 
susceptible to cell death. Despite this anti-apoptotic effect, tumors ultimately recur and I 
investigated mechanisms that support this phenomenon. I show Bcl-xL deleted tumors 
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select for proliferating cells to evade BCL-xL dependence and that MCL-1 may 
contribute to the protection of proliferating Bcl-xL deleted tumor cells. Thus, blocking 
SHH proliferation which reduces MCL-1 abundance in tumors and inhibiting BCL-xL 
function may be of therapeutic benefit in SHH-driven medulloblastoma tumors. These 
findings are corroborated by differential gene expression analysis in Bcl-xL deleted 
tumors, which also revealed a potential role for tumor associated macrophages in 
contributing to the tumor phenotype. All together my data show that intricate apoptotic 
mechanisms present in the developing cerebellum also contribute to the regulation of 
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CHAPTER ONE: INTRODUCTION 
 
1.1 Review of Apoptosis 
 
The mammalian apoptotic pathway  
Apoptosis is an evolutionarily conserved process that functions during normal 
development to cull damaged or superfluous cells and is responsible for maintaining 
tissue homeostasis1,2. The heightened cellular proliferation that is a hallmark of 
development must be negatively regulated by apoptosis to ensure proper limb and 
organ formation during embryogenesis3. Dysfunctional apoptosis can lead to excessive 
or inadequate cell death and contributes to numerous pathologies across tissue types 
including neurodegenerative and autoimmune diseases as well as cancer4–8.  
Whether functioning in a physiological or pathological role, apoptosis ultimately 
leads to the activation of cysteine-aspartic proteases (caspases), which dismantle 
cellular components in a controlled manner to minimize stress to surrounding cells and 
tissues9. Caspase activation is initiated by two distinct pathways: extrinsic or intrinsic 
apoptosis10,11. The extrinsic, or death-receptor mediated pathway, is triggered by ligand 
binding to cell-surface receptors, while the intrinsic pathway is triggered by numerous 
internal signals of cellular stress. A major distinguishing factor between intrinsic and 
extrinsic apoptosis is the direct involvement of the mitochondria in initiating cell death. 
While the extrinsic pathway initially bypasses the mitochondria through direct activation 
of caspase-8, intrinsic apoptosis requires mitochondrial outer membrane 
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permeabilization (MOMP) and cytochrome c (CytoC) release for the downstream 
activation of caspases12. The remainder of this dissertation will focus on explaining 
mechanisms of the intrinsic apoptosis pathway.  
Intrinsic apoptosis pathway  
Intrinsic apoptosis is provoked in response to numerous cell stressors, most 
notably by trophic factor deprivation, DNA damage, or endoplasmic reticulum (ER) 
stress12–15. Downstream signaling of these events are stimulus-specific. Genotoxic 
insults lead to activation of p53, while trophic factor deprivation results in decreased 
Protein Kinase B/Akt signaling and activation of c-Jun N-terminal kinase. Ultimately, 
these signaling cascades intersect by activating a tightly regulated family of proteins 
responsible for maintaining mitochondrial membrane integrity known as the B-cell 
lymphoma-2 (BCL-2) family16. These guardians of the mitochondria orchestrate MOMP, 
which is generally considered the critical step for commitment to apoptosis via the 
intrinsic pathway17 (Figure 1).  
The BCL-2 family of proteins 
The founding member of the protein family, BCL-2,  was discovered in 1984 as a 
putative oncogene in acute lymphoblastic leukemia18 , and 4 years later was shown to 
protect hematopoietic cells from apoptosis19. Shortly after, MCL-1 (myeloid cell 
leukemia 1) was identified in ML-1 myeloid leukemia cells as an immediate early gene 
expressed during differentiation20. The discoveries of BCL-2 and MCL-1 gave rise to a 
new class of oncogenes that preserved cellular viability through inhibition of apoptosis19,  
which has since become a hallmark of many cancers8. Since these seminal discoveries, 
numerous family members have been identified based on conserved motifs known as 
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BCL-2 homology (BH) motifs, which allow BCL-2 proteins to interact with each other 
and define their role within the apoptotic pathway21,22. Members of the BCL-2 family are 
traditionally classified into 3 subcategories: BH3-only proteins (pro-apoptotic), pore-
forming or ‘executioner’ proteins (pro-apoptotic) and anti-apoptotic proteins (Figure 2). 
The apoptotic fate of a cell is determined by the competitive flux of these proteins22 and 
their respective functions are discussed below.   
First responders: BH3-only proteins 
The first responders to apoptotic stimuli are a subset of pro-apoptotic members 
known as BH3-only proteins, named for the single BH3 domain they contain. BH3-only 
“activators” (e.g., BID, BIM, PUMA) can directly engage pro-apoptotic pore-forming 
proteins BAX and BAK causing MOMP21,22. BIM has a higher affinity for activating BAX, 
while the truncated, active form of BID (tBID) binds more efficiently with BAK23–25. BH3-
only “sensitizers” (e.g., BAD, BMF, HRK/DP5, NOXA) have a low affinity for BAX and 
BAK.  Instead, BH3-only “sensitizers” sequester anti-apoptotic family members 
preventing their interaction with BAX or BAK 21, 22.  
Pore-forming executioners: BAX and BAK 
Genetic deletion studies have been vital for uncovering the pro-apoptotic 
functions of BAX and BAK. Mice with deletion of Bax26 or Bak3 only are viable and suffer 
mild developmental abnormalities, but most mice die perinatally from combined deletion 
of Bax and Bak. The few mice that survive to adulthood have multiple deformities 
including persistent interdigital webbing, an imperforate vaginal canal and excess cells 
in the nervous system and hematopoietic system3. Various cell types derived from these 
mice fail to undergo apoptosis when challenged with cytotoxic stimuli or overexpression 
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of BH3-only proteins27,28, establishing that BAX and BAK act downstream of BH3-only 
proteins. 
 Interactions between BH3-only proteins and the executioner proteins BAX and 
BAK vary across cell types and stress signals, however the mechanism of activation is 
relatively preserved. BAX and BAK contain BH1, BH2, BH3, and transmembrane (TM) 
protein domains (Figure 2). Typically in healthy cells, BAX exists as a cytosolic 
monomer with the TM domain sequestered in a hydrophobic groove, and BAK is 
constitutively localized in the outer mitochondrial membrane (OMM). BH3-only 
activation of BAX leads to a conformational change that reveals the TM domain and 
promotes insertion into the mitochondrial membrane. Once activated, BAX and BAK 
oligomerize and form pores in the OMM, consequently releasing cytochrome c into the 
cytosol 22,29.  
Despite the conserved mechanism of BH-3 dependent activation of BAX and 
BAK, various cell types have inherently different susceptibilities to apoptotic stimuli. 
Healthy brain, heart, and kidney cells are relatively apoptosis refractory, and restrict 
expression of BAX and/or BAK. Conversely, in early life these cells are “primed for 
apoptosis”, expressing high levels of BH-3 only activators to respond to a low threshold 
of apoptotic stimuli30. Apoptotic priming can also be achieved through expression of 
constitutively active BAX31,32. Human embryonic stem (hES) cells maintain active BAX 
at the Golgi31, whereas cerebellar granule neural progenitors (CGNPs) keep active BAX 
at the mitochondrial membrane, bound to anti-apoptotic BCL-xL32 and both instances 
result in rapid induction of apoptosis after DNA damage.  
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Anti-apoptotic BCL-2 family members 
The primary function of anti-apoptotic BCL-2 family members are to bind pore-
forming executioners to prevent MOMP. Anti-apoptotic BCL-2 family members (e.g., 
BCL-2, MCL-1 ,BCL-xL and BCL-W) have a TM domain and 4 total BH domains, 
including a BH4 domain which distinguishes them from executioner proteins22. Similar to 
other BCL-2 family members, the distribution and importance of specific anti-apoptotic 
proteins to preserve cells is diverse across tissue type and developmental stages.  
After mitochondrial outer membrane permeabilization  
Puncturing of the OMM is considered the critical event for commitment to 
apoptosis, however there are many steps downstream required for the completion of 
apoptosis. After MOMP, proteins from the mitochondrial intermembrane space are 
released into the cytosol. These proteins include CytoC, SMAC/DIABLO, OMI/HtrA2, 
EndoG and AIF. Cytochrome C binds to APAF-1, creating the apoptosome, which 
activates the initiator caspase, Caspase 9. Once activated, Caspase 9 orchestrates the 
cleavage of effector caspases Caspase 7 and Caspase 3. The effector caspases are 
then responsible for cleavage of intracellular proteins, beginning tightly regulated 
dismantlement of the cell. Caspase activation can be blocked by the cytosolic protein 
XIAP (X-linked inhibitor of apoptosis), but the presence of SMAC/DIABLO and 
OMI/HtrA2 after MOMP neutralize this inhibition (Figure 3). Lastly, after release into the 
cytosol, EndoG and AIF translocate to the nucleus where they promote chromatin 
condensation and DNA fragmentation33.  
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Apoptosis in the developing cerebellum 
Apoptotic regulation is critical for proper cerebellar development32,34. Proliferating 
CGNPs are highly vulnerable to apoptosis in response to DNA damage, as seen when 
the P7 cerebellum is exposed to ionizing radiation35. In mice with deletion of Aspm, a 
gene mutated in familial microcephaly, replication stress can also trigger CGNP 
apoptosis, causing cerebellar hypoplasia36. Additionally, exposure to glucocorticoids 
during the neonatal period can provoke widespread CGNP apoptosis37. Because 
apoptosis triggered by each of these stimuli can significantly impair cerebellar growth 
and function, molecular controls of apoptosis are essential. However, the requirement of 
specific BCL-2 family members in the regulation of apoptosis over the course of 
cerebellar development remains uninvestigated and is a major avenue of inquiry in this 
dissertation.  
BCL-xL and MCL-1 are both expressed in the cerebellum32,38,39, while BCL-2 
expression is relatively low39. MCL-1 expression in the cerebellum is subject to 
developmental regulation through IGF-140,  a signaling pathway that interacts with sonic 
hedgehog signaling (SHH) in CGNPs41,42. However, Mcl-1 deletion does not impair 
cerebellar growth32, raising the question of whether MCL-1 function is essential in 
CGNPs. In contrast, BCL-xL is essential for embryonic brain development43, but the role 
of BCL-xL in the post-natal development of the cerebellum has not been determined. 
Our previous studies have shown CGNPs maintain BAX in an active conformation, 
complexed to BCL-xL32, but it is unknown if BCL-xL is essential for CGNP survival 
throughout cerebellar development.   
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1.2 Review of Cerebellar Development and Medulloblastoma 
Basic cerebellar anatomy 
The cerebellum has been well studied for over a century. Pioneering studies 
published in 1888 by Ramón y Cajal unraveled the basic circuitry of the cerebellar 
cortex and laid the foundation for our current breadth of knowledge44. The mature 
cerebellar cortex has a simple laminar structure comprised of two primary neuronal 
types: the cerebellar granule neuron and the Purkinje cell. Granule neurons (CGNs) 
receive afferent, excitatory input and coordinate motor output through excitatory 
interactions with Purkinje cells, which are the sole output neurons of the cerebellum. 
Output of the Purkinje cell to the cerebellar nuclei is modulated by diverse interneurons 
(e.g., unipolar brush, Golgi, stellate, basket, and Lugaro cells)45,46. Neurons of the 
cerebellum emerge from two distinct germinal zones: the ventricular zone and rhombic 
lip. The rhombic lip gives rise to CGNPs (CGN precursor cells), and the transient 
amplification of these cells during the postnatal period forms the largest population of 
neurons in the brain47,48.  
Postnatal cerebellar neurogenesis 
Postnatal cerebellar neurogenesis continues throughout the first year of life in 
humans49 and the first 2 weeks of life in mice50,51. During this time, CGNPs proliferate in 
the external granule layer (EGL) along the outside of the cerebellum, in response to 
SHH secreted locally by Purkinje neurons (Figure 4) 52–55. CGNPs and their precursors 
specifically express the transcription factor MATH1(Atoh1) beginning at E12.556, and the 
Math1 promoter can be used to target Cre-mediated recombination to these cells57.   
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Proliferation of CGNPs in the EGL peaks at P7 in mice and then wanes until P15. 
This proliferation is negatively regulated by BAX-dependent apoptosis34 and by p27-
mediated differentiation58–61, which combine to control population growth and prevent 
tumor formation. Within the EGL, CGNPs segregate into a proliferating, PCNA+ outer 
layer (oEGL) that expresses PCNA and phosphorylated Rb (pRB), and a differentiating, 
inner layer (iEGL) that expresses p27 (Figure 5). Post-mitotic, p27+ CGNPs migrate 
from the iEGL along radial glia processes in progressively greater numbers to populate 
the internal granule layer (IGL). In the IGL, CGNPs complete terminal differentiation, to 
become mature CGNs and incorporate into local and long range circuitry.  By P20 the 
EGL is depopulated and cerebellar neurogenesis is complete49,62. 
Excessive SHH stimulation can cause CGNP proliferation to degenerate into 
tumorigenesis and SHH-pathway activation is responsible for 30% of medulloblastoma 
cases63. Hyper-activation of SHH signaling in transgenic mice, induced, for example, by 
mutation of the SHH effector SMO, prolongs CGNP proliferation and causes tumors to 
form that resemble human medulloblastoma in both histology and transcription 
profile64,65. These tumors show that SHH-driven medulloblastomas derive from CGNPs 
and share diverse biological processes, including metabolic specialization66 and 
apoptosis regulation32. This also underscores the importance of understanding how 
normal developmental processes function to control aberrant SHH signaling, as these 
may also participate in medulloblastoma tumorigenesis.   
Medulloblastoma classifications   
Medulloblastoma (MB) is the most prevalent brain tumor in children. Pioneering 
studies in the 1920’s by Harvey Cushing and Percival Bailey were the first to describe 
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clinical and histopathological characteristics of MB. At the time, Cushing and Bailey 
described MB as a subset of gliomas, however their work laid the foundation for 
decades of research into the origins, classification and treatment of this devastating 
disease67–69.   
Since these initial studies, modern advancements in molecular genetics have 
revolutionized our understanding of medulloblastoma. The first gene expression array 
analysis of embryonal tumors showed MB unequivocally differed from other brain 
tumors including malignant gliomas, primitive neuroectodermal tumors (PNETs) and 
atypical teratoid/rhabdoid tumors (AT/RTs)70. Multiple research groups have since 
published independent transcriptional analyses leading to a consensus in the field of 4 
genetically distinct subtypes: WNT, SHH, Group 3 and Group 4 71–75 (Figure 6). In 2016, 
these stratifications were adopted in the World Health Organization’s classification of 
CNS tumors76.  Most recently, subtypes within SHH, Group 3 and Group 4 have been 
further classified based on differences in age at onset, prognosis, and molecular 
heterogeneity77–79.  
The comprehensive analysis of molecular and clinical heterogeneity provided by 
these studies are vital for progressing MB treatments. However, adapting MB therapy to 
reflect differences in disease biology is only in the early stages. The original research of 
this dissertation contributes to this emerging field by characterizing mechanisms 
controlling tumor growth in the SHH subtype of medulloblastoma that may prove useful 
for treatment.   
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SHH subtype of medulloblastoma 
Approximately one third of all diagnosed MB cases fall into the SHH-subgroup80. 
Age at onset in patients is bimodal, being most frequently observed in infants (0-3 
years) and adults (>16 years), and less frequently seen in children (3-16 years). Males 
and females are equally impacted, and overall survival varies according to clinical and 
molecular traits (Figure 6)81.  
The genetic underpinnings of the SHH subgroup are well characterized. Most 
patients present with germline or somatic mutations and copy number alterations in 
genes crucial for canonical SHH signaling. All of these disruptions lead to hyperactive, 
ligand independent SHH signaling that drives consistent transcription of proliferation 
associated genes. The most frequent mutations include loss-of-function mutations or 
deletions in PTCH1 (43%) or SUFU (10%). Additionally, SMO activating mutations (9%) 
or amplification of GLl1, GLI2 (9%) or MYCN (7%) are commonly observed 82,83. 
Recurrent copy number alterations in the PI3K (10%) and TP53 (9.4%) pathways have 
also been reported as key drivers of MB tumorigenesis84, and TP53 mutations are 
associated with poor prognosis85.   
Recent gene expression array and DNA methylation data have further stratified 
SHH-driven medulloblastoma into 4 subtypes: SHHα, SHHβ, SHHγ and SHHδ 78.  
SHHα occurs predominantly in children, with frequent mutations in TP53 and 
amplifications of MYCN and GLI2. SHHβ and SHHγ both occur in infants, however 
SHHβ is often metastatic and associated with poorer outcome than SHHγ. Lastly, SHHδ 
in comprised of adult patients with enrichment in TERT (telomerase reverse 
transcriptase) promoter mutations78. The implications of greater TERT mutations in 
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adult SHH-MB is unknown, but suggests a key difference in telomere maintenance 
compared to infants and children. Despite these new molecular insights, advancements 
in MB therapy are currently lagging, given the standard course of treatment has 
remained largely the same since the 1970s when cytotoxic chemotherapy agents were 
implemented in clinical trials81.  
Medulloblastoma treatment 
Two-thirds of MB patients are considered standard risk, defined as patients 
between the ages of 3-18 years without metastatic disease having undergone near-total 
tumor resection. For patients in this cohort, following resection with irradiation of the 
entire cranio-spinal axis and adjuvant chemotherapy (e.g., cisplatin, vincristine, 
cyclophosphamide or lomustine) leads to a 5-year survival rate of 80%86–88. The 
success of these treatments rely on the sensitivity of MB to DNA damage and are highly 
toxic to patients, especially infants. Most notably, survivors suffer from endocrine failure, 
growth impairment, and severe cognitive deficits, while enduring the risk of early strokes 
and tumor recurrence89,90. Ultimately, 20 percent of patients die from tumor recurrence. 
New treatments are needed to cure patients with recurrent MB, to minimize toxicity for 
standard risk patients, and to account for subtype specific molecular profiles.  
SHH inhibition has been recognized as a promising new approach to treating 
many cancers that derive from tissues dependent on SHH signaling in development, 
including the bladder91, GI system92, and brain93,94. In medulloblastoma, recent studies 
have tested small molecule SMO inhibitors such as Vismodegib (Vismo) and 
Erismodegib95, however the efficacy of these agents has been limited by spontaneous 
mutations that confer resistance96–99. The development of resistance limits the potential 
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of SMO inhibition as a monotherapy, and current studies are investigating downstream 
targets of the SHH pathway. The protein kinase CK2 has recently emerged as a 
potential target, and Phase 1/Phase 2 clinical trials are underway using the CK2 
inhibitor CX-4945 in children with recurrent medulloblastoma (NCT03904862)100 . In the 
future, applying the modern advancements in molecular genetics to identify potential 







1.3 Figures and Legends 
Figure 1. Intrinsic apoptosis pathway in mammalian cells 
Simplified schematic showing initiation of intrinsic apoptosis by various apoptotic stimuli 
which result in activation of BH3-only proteins. BH3-only proteins activate pro-apoptotic 
proteins BAX or BAK (activators), or sequester pro-survival proteins (sensitizers). 
Activation of BAX/BAK leads to oligomerization, pore formation and permeabilization of 
the mitochondrial outer membrane (MOMP). Subsequent cytochrome c (CytoC) release 








Figure 2. Classification of BCL-2 family proteins 
Pro-apoptotic and anti-apoptotic members of the BCL-2 family showing classification via 
number of BCL-2 homology (BH) domains. Anti-apoptotic BCL-2, BCL-xL, MCL-1 and 
BCL-W contain 4 BH domains along with a transmembrane (TM) domain which allows 
for insertion into the mitochondrial membrane. Pro-apoptotic BAX and BAK contain a 
TM domain and 3 BH domains. The aptly named “BH3-only” proteins (BIM, PUMA, 
NOXA, HRK/DP5, BAD, BID, and BMF) contain only the BH3 domain and are strictly 






Figure 3. Events downstream of MOMP                                                                     
After MOMP, CytoC binds APAF-1, creating the apoptosome that activates Caspase 9. 
Caspase 9 then cleaves and activates effector caspases, which promote cleavage of 
intra-cellular proteins and the dismantlement of the cell. XIAP can inhibit effector 
caspases, and this is neutralized by the release of SMAC and OMI into the cytosol after 









Figure 4. SHH signaling in CGNPs                                                                           
Simplified schematic showing SHH signaling pathway in CGNPs. In an inactive state, 
the transmembrane protein Patched (PTCH) inhibits Smoothened (SMO) preventing 
downstream signaling. In the presence of extracellular SHH, PTCH inhibition of SMO is 
released activating GLI2. GLI2 translocates to the nucleus and promotes transcription of 
proliferation genes CyclinD1 and N-myc. GLI2 also promotes transcription of Ptch and 








Figure 5. SHH regulation of cerebellar development                                       
Cerebellar neurogenesis is marked by a rapid increase in proliferation of CGNPS in the 
external granule layer (EGL) in response to SHH signaling from purkinje cells. The EGL 
separates into two distinct layers: proliferating, PCNA+ outer EGL (oEGL) and 
differentiating, p27+ inner EGL (iEGL). Differentiated neurons migrate along radial glial 








Figure 6. Current subtype classifications of medulloblastoma                            
Clinical and molecular characteristics of the 4 genetically distinct subtypes of 
medulloblastoma. Adapted from Juraschka and Taylor (2019)81 and based on data from 








CHAPTER TWO: ANTIAPOPTOTIC BCL-2 FAMILY PROTEINS BCL-XL AND MCL-1 
INTEGRATE NEURAL PROGENITOR SURVIVAL AND PROLIFERATION DURING 




The tendency of brain cells to undergo apoptosis in response to exogenous 
events varies across neural development, with apoptotic threshold dependent on 
proliferation state. Proliferative neural progenitors show a low threshold for apoptosis, 
while terminally differentiated neurons are relatively refractory. To define the 
mechanisms linking proliferation and apoptotic threshold, we examined the effect of 
conditionally deleting Bcl2l1, the gene that codes the anti-apoptotic protein BCL-xL, in 
cerebellar granule neuron progenitors (CGNPs), and of co-deleting Bcl2l1 homologs, 
anti-apoptotic Mcl-1 or pro-apoptotic Bax. We found that cerebella in conditional Bcl2l1-
deleted (Bcl-xLcKO) mice were severely hypoplastic due to increased apoptosis of 
CGNPs and their differentiated progeny, the cerebellar granule neurons (CGNs). 
Apoptosis was highest as Bcl-xLcKO CGNPs exited the cell cycle to initiate 
differentiation, with proliferating Bcl-xLcKO CGNPs relatively less affected. Despite the 
overall reduction in cerebellar growth, SHH-dependent proliferation was prolonged in 
Bcl-xLcKO mice, as more CGNPs remained proliferative in the second postnatal week. 
Co-deletion of Bax rescued the Bcl-xLcKO phenotype, while co-deletion of MCL-1 
enhanced the phenotype. These findings show that CGNPs require BCL-xL to regulate 
BAX-dependent apoptosis, and that this role can be partially compensated by MCL-1. 
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Our data further show that BCL-xL expression is required for the regulation of MCL-1 in 
CGNPs, and suggest that excessive MCL-1 in Bcl-xLcKO mice prolongs CGNP 
proliferation by amplifying SHH signaling. Based on these findings, we propose that 
anti-apoptotic BCL-xL and MCL-1 interact with each other and with mitogenic 
mechanisms to regulate apoptotic threshold as CGNPs progress through postnatal 





In the developing nervous system, the apoptotic decisions of individual cells have 
risks and benefits to the organism that vary with proliferative state. Early in 
development, apoptosis of dividing progenitors can inappropriately limit growth by 
ablating the potential progeny of the dividing cell. However, the apoptosis of DNA-
damaged progenitors can be advantageous in preventing the propagation of mutations. 
The risks of apoptosis change as progenitor self-renewal decreases. Progenitors with 
limited self-renewal have fewer progeny, reducing the risk that their apoptosis will impair 
growth. Later in development, when progenitors have exited the cell cycle and 
differentiated into neurons, the implications of apoptotic decisions are again different. If 
mature neurons sustain DNA damage, there is no risk of propagating mutations, but the 
cell cannot be replaced through proliferation if it undergoes apoptosis. We propose that 
these different risks and benefits shape the mechanisms that regulate apoptosis in early 
progenitors, late progenitors and neurons, and that these mechanisms can be 
elucidated in the developmental progression of CGNPs to CGNs.  
CGNPs proliferate in the external granule layer (EGL) of the cerebellum, during 
the first 15 days of life in mice, and the first year of life in humans, in response to locally 
secreted Sonic Hedgehog (SHH). In mice, CGNP proliferation wanes from P7-15, as 
individual CGNPs exit the cell cycle, moving from the proliferative outer EGL (oEGL), 
distinguished by proliferation markers PCNA and phosphorylated RB (pRB), to the 
differentiating inner EGL (iEGL). Differentiating CGNPs then migrate to the internal 
granule layer (IGL) to become terminally differentiated CGNs 46,101,102. 
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We have shown that CGNPs are primed for apoptosis by maintaining pro-
apoptotic BAX in an active conformation103. Most cell types maintain BAX in its inactive 
conformation unless apoptosis is initiated. However, CGNPs, like other proliferative cell 
types, maintain a state of apoptotic priming in which BAX is kept in its active 
conformation, bound to anti-apoptotic proteins to prevent spontaneous 
apoptosis30,31,104,105. Apoptotic priming reduces the threshold stimulus required to trigger 
cell death. Consistent with apoptotic priming, our lab showed that CGNPs harbor active 
BAX complexed with BCL-xL, and that pro-apoptotic stimulus disrupted the BCL-xL:BAX 
interaction103. These findings suggest that CGNPs use BCL-xL to prevent inappropriate 
triggering of apoptosis, but do not resolve how CGNPs regulate apoptotic threshold over 
the course of neuronal differentiation.  
Prior studies have shown BCL-xL dependence increases with differentiation. 
Conditional deletion of Bcl2l1, the locus that encodes Bcl-xL, causes neurons 
throughout the central nervous system, including retinal ganglion cells and neurons of 
the cerebral cortex and spinal cord, to undergo apoptosis after differentiating from 
progenitors106–109.  These studies of different CNS regions show a consistent pattern in 
which BCL-xL is required for neuronal survival. However, the role of BCL-xL in 
progenitors is unclear, and remains complicated by divergent requirements for the BCL-
xL homolog MCL-1 in different experimental contexts. 
Conditional deletion studies of Mcl-1 in the nervous system have produced 
conflicting results on progenitor dependence. Studies using one conditional mouse line 
showed marked phenotypes caused by Mcl-1 deletion, with apoptosis of embryonic and 
adult neural progenitors109–111. However, our lab found that conditional deletion of Mcl-1 
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in cerebellar progenitors, using an independently generated conditional mouse line, did 
not induce CGNP apoptosis and produced no detectable phenotype103. Both Mcl-1 
conditional deletion lines similarly harbor loxP sites surrounding the first exon, and the 
reason for the divergence in phenotypes is not clear.  
We investigated the developmental dynamics of apoptosis regulation in the CNS 
by conditionally deleting Bcl2l1 in the CGNP lineage, either alone or in combination with 
either Mcl-1 or Bax. Our data show an interrelation between anti-apoptotic proteins that 
changes over the course of postnatal cerebellar neurogenesis, affects mitogenic 
signaling and differs from prior findings in cerebral development.   
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2.3 Results  
 
Bcl-xL deletion in CGNPs reduces cerebellar growth while prolonging progenitor 
proliferation 
Our prior finding that CGNPs maintain the pro-apoptotic protein BAX in its 
activated conformation suggested that these cells would require an anti-apoptotic 
mechanism to prevent spontaneous apoptosis103. To determine if CGNPs depended on 
BCL-xL, we conditionally deleted Bcl2l1 in the Math-1 lineage. Math-1 is a transcription 
factor expressed in a rostro-caudal pattern by CGNPs beginning at embryonic day 12.5 
(E12.5)112–114. We bred Math1-Cre and Bcl2l loxP/loxP mice 115 to generate Math1-
Cre/Bcl2l1loxP/loxP  (Bcl-xLcKO) animals. We then compared Bcl-xLcKO mice to littermate 
controls, including Math1-Cre/Bcl2l1loxP/+ (Bcl-xLHET) mice with heterozygous Bcl2l1 
deletion and mice without Cre, in which both alleles of Bcl2l1 remained intact.  
We found that Bcl2l1 deletion caused severe, symptomatic cerebellar hypoplasia. 
Bcl-xLcKO mice were viable and fertile, but exhibited ataxia by P12, when pups begin to 
ambulate. The cerebella of Bcl-xLcKO mice showed normal anatomy up to P7 (Fig. 1A). 
However, after P7 cerebellar growth decreased, and by P12 Bcl-xLcKO cerebella were 
notably smaller than controls, with marked thinning of the CGNs of the IGL (Fig. 1A). 
Reduced cerebellar size and thinning of the IGL population became more pronounced 
by P20 (Fig. 1A). 
We noted that the 2-4 most posterior-inferior lobules of the cerebella were 
relatively preserved in Bcl-xLcKO cerebella (Fig. 1A). Math1-cre has been shown to 
delete target genes less efficiently in this region116. To determine if inefficient deletion of 
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Bcl2l1 accounted for the preservation of the posterior-inferior region, we compared 
BCL-xL protein distribution in P7 Bcl-xLcKO and control cerebella. We found that BCL-xL 
protein was absent in the EGL of Bcl-xLcKO mice, except in the most posterior-inferior 
lobules, whereas BCL-xL was present through the cerebellum in controls, including the 
entire EGL (Fig. 1B). Because Bcl2l1 was not effectively deleted in the posterior-inferior 
region, as demonstrated by persistent BCL-xL protein, we focus in the rest of the 
analysis on anterior-superior lobules of the cerebellum in which BCL-xL was effectively 
ablated.   
In light of the overall reduction in cerebellar growth, we were surprised to find that 
the proliferative CGNP population was increased at P12 in Bcl-xLcKO cerebella. We 
noted that the EGL was abnormally thick in P12 Bcl-xLcKO mice, compared to P12 
controls, in which the EGL is expected to have thinned from its peak thickness at P7 
(Fig. 1A). The thickened EGL in P12 Bcl-xLcKO cerebella showed increased fractions of 
CGNPs expressing the proliferation marker pRB and the mitotic marker pHH3 (Fig. 1C, 
D, E, F). Thus, the Bcl-xLcKO phenotype included two key features: reduced population 
of CGNs of the IGL and prolonged CGNP proliferation in the EGL. 
 
BAX-dependent CGNP apoptosis drives growth failure in Bcl-xLcKO cerebella 
To determine if cerebellar hypoplasia in Bcl-xLcKO mice resulted from increased 
apoptosis, we compared the apoptotic rate in Bcl-xLcKO and control mice and 
determined whether Bax co-deletion rescued cerebellar growth. At P7, Bcl-xLcKO 
cerebella showed increased fractions of cells expressing the apoptosis marker cleaved 
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caspase-3 (cC3) compared to controls; apoptosis was increased in both the 
undifferentiated CGNPs of the EGL and the differentiated CGNs of the IGL (Fig. 2A,B).  
To determine the contribution of BAX to this increased apoptosis, we co-deleted 
Bcl2l1 and Bax by breeding Bcl-xLcKO and Bax loxP/loxP lines to generate Math1-
Cre;Bcl2l1loxP/loxP;BaxloxP/loxP (Bcl-xL;BaxdKO) mice. Bcl-xL;BaxdKO mice were viable and 
fertile and unlike the Bcl-xLcKO, did not develop ataxia. The frequency of apoptosis in P7 
Bcl-xL;BaxdKO EGL and IGL was similar to WT controls (Fig. 2A,B). Cerebellar anatomy 
and development were normal in Bcl-xL;BaxdKO mice (Fig. 2C). The rescue of both 
increased apoptosis at P7 and cerebellar hypoplasia in Bcl-xL;BaxdKO mice establish 
BAX-dependent apoptosis as the primary cause of growth failure in the Bcl-xLcKO 
phenotype.  
Apoptosis remained increased in Bcl-xLcKO cerebella at P12, and this increase 
was reduced, but not normalized in Bcl-xL;BaxdKO mice (Fig. 2D,E), The increased 
proliferation noted in the EGL in P12 Bcl-xLcKO mice was not observed in Bcl-xL;BaxdKO 
mice (Fig. 2F,G).  Bax co-deletion thus rescued both the cerebellar hypoplasia and the 
prolonged CGNP proliferation of the Bcl-xLcKO phenotype, demonstrating that BCL-xL 
acts in CGNPs predominantly through its interaction with BAX. However, the statistically 
significant increase in CGNP apoptosis in the P12 Bcl-xL;BaxdKO cerebella shows that 
BCL-xL interacts with additional death regulators that operate in parallel with BAX, 




Apoptosis in Bcl-xLcKO CGNPs increases with cell cycle exit   
CGNPs progress through proliferative and post-proliferative, undifferentiated 
stages, which made it possible for us to examine the effects of cell cycle exit on BCL-xL 
dependence, prior to completion of neuronal differentiation. While the increased cell 
death in the Bcl-xLcKO IGL showed BCL-xL dependence in early differentiated neurons, 
consistent with prior reports106–109; comparison of the oEGL and iEGL allowed us to 
specifically determine a link between BCL-xL-dependence and post-proliferative state. 
To analyze cell death in the oEGL and iEGL, we compared the co-expression of cC3 
and PCNA in Bcl-xLcKO , Bcl-xL;BaxdKO  and control cerebella at P7. We found increased 
apoptosis in Bcl-xLcKO CGNPs in both the PCNA+ oEGL and the PCNA- iEGL (Fig 
3A,B), demonstrating that CGNPs depend on BCL-xL before and after cell cycle exit.  In 
controls, apoptosis was more frequent in proliferating CGNPs, such that the log ratio of 
apoptotic cells in PCNA-:PCNA+ layers was negative, however, in the Bcl-xLcKO mice, 
this relationship was reversed, with apoptosis higher in the PCNA- population (Fig. 3C). 
Conversely, we noted in flow cytometry studies that at P7 the pRB+ fraction of CGNPs 
was larger in the in the Bcl-xLcKO cerebella (Fig. 3D,E), consistent with selective removal 
of differentiating cells from the CGNP population.  
 
Interaction between BCL-xL function and differentiation 
 To test experimentally whether BCL-xL dependence was causally linked to 
differentiation, we examined the effect of accelerating CGNP cell cycle exit by 
administering the SHH pathway inhibitor vismodegib to Bcl-xLcKO and control mice. 
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Vismodegib blocks SHH signaling by inhibiting the SHH receptor component SMO117,118. 
To facilitate vismodegib administration, we used the recently developed nanoparticle 
formulation (POx-vismo)119. In both Bcl-xLcKO mice and controls, daily administration of 
vismodegib over a 2-day period from P5-7 significantly increased cell cycle exit, 
demonstrated by reduced fractions of PCNA+ cells at P7 (Fig. 3F,G). Importantly, 
vismodegib depleted the EGL population significantly more in Bcl-xLcKO mice than in 
controls, showing greater effect on both total cell density and density of PCNA+ cells 
(Fig. 3H,I). The greater reduction of the EGL by vismodegib in Bcl-xLcKO mice is 
consistent with the induced differentiation in the absence of BCL-xL increasing cell 
death. It is also possible that Bcl2l1-deletion may potentiate induction of differentiation 
by vismodegib, and that both processes may act in concert. In either case, the data 
show that BCL-xL function remains linked to CGNP cell cycle exit when cell cycle exit is 
accelerated.  
 
CGNPs express MCL-1 during proliferation 
To identify a mechanism for reduced BCL-xL dependence during proliferation, we 
analyzed the expression of the BCL-xL homolog, MCL-1 in WT CGNPs at different 
phases of the cell cycle. We found that MCL-1 expression in CGNPs varied across the 
cell cycle. CGNPs at G0/G1 showed a range of MCL-1 expression from detectable to 
undetectable, while CGNPs at S-G2/M were consistently MCL-1+, demonstrating both a 
higher fraction above threshold and a higher median fluorescence intensity (Fig. 4A,B). 
This proliferation-specific expression pattern identified MCL-1 as a potential mechanism 
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that could compensate for the loss of BCL-xL in Bcl-xLcKO CGNPs during their 
proliferation.  
 
BCL-xL depletion in Bcl-xLcKO CGNPs increases MCL-1 protein abundance  
 We noted in flow cytometry studies that MCL-1 staining was markedly more 
intense in CGNPs from Bcl-xLcKO mice compared to CGNPs from Bcl-xL-intact controls, 
indicating that individual Bcl-xLcKO CGNPs contained more MCL-1 protein (Fig. 4C,D). 
Western blot studies confirmed increased MCL-1 abundance in Bcl-xLcKO cerebellar 
lysates (Fig. 4E,F). Increased MCL-1 likely represents a change in MCL-1 stability, as 
MCL-1 abundance is regulated by post-translational degradation120–122 The increased 
MCL-1 in Bcl-xLcKO CGNPs suggests a homeostatic mechanism in which MCL-1 stability 
increases in response to reduced BCL-xL.  
 
MCL-1 compensates for BCL-xL in proliferating CGNPs  
To test directly whether MCL-1 may compensate for BCL-xL, potentially 
maintaining the survival of proliferating CGNPs in Bcl-xLcKO mice, we generated animals 
with co-deletion of Mcl-1 and Bcl2l1. We accomplished this co-deletion by breeding Bcl-
xLcKO mice  with Mcl-1loxP/loxP 123 mice to create the Math1-Cre;Bcl2l1loxP/loxP;Mcl-1loxP/loxP   
(Bcl-xL;Mcl-1dKO) genotype. As an intermediate in the course of this breeding, we also 
generated Math1-Cre;Bcl2l1loxP/+;Mcl-1loxP/loxP mice that carried Math1-Cre and were 
heterozygous for Bcl2l1 and homozygous for Mcl-1 (Bcl-xLHET;Mcl-1cKO). Bcl-xLHET;Mcl-
1cKO mice developed mild cerebellar hypoplasia (Fig. 5A) that was not symptomatic. 
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This hypoplasia was in contrast to the normal appearing cerebella of both Math1-
Cre;Bcl2l1loxP/+ (Bcl-xLHET) mice where Bcl2l1 was heterozygous and Mcl-1 was WT, 
and Math1-Cre;Mcl-1loxP/ loxP (Mcl-1cKO) mice where Bcl2l1 was WT and Mcl-1 was 
deleted (Fig. 5A). The phenotype of Bcl-xLHET;Mcl-1cKO show that Bcl2l1 heterozygosity 
induced a requirement for MCL-1 that was not apparent when Bcl2l1 was WT, and 
similarly, that Mcl-1 deletion, induced a requirement for both copies of Bcl2l1 to be 
intact.  The intermediate Bcl-xLHET;Mcl-1cKO genotype thus provided initial evidence that 
BCL-xL and MCL-1 operate redundantly in CGNPs.  
Homozygous conditional deletion of Bcl2l1 and Mcl-1 in Bcl-xL;Mcl-1dKO mice 
produced more severe cerebellar growth failure than Bcl-xLHET;Mcl-1cKO mice. Like Bcl-
xLcKO mice, Bcl-xL;Mcl-1dKO mice were ataxic but viable and fertile. However, growth 
failure began earlier than in Bcl-xLcKO mice, as cerebella in Bcl-xL;Mcl-1dKO mice 
showed markedly reduced size and foliation beginning as early as P7, with sparing of 
the posterior-inferior region producing a sharply contrasting region by P16 (Fig. 5B). 
Apoptosis was also distributed differently, localizing primarily to the EGL of Bcl-xL;Mcl-
1dKO cerebella and occurred primarily in proliferating, PCNA+ CGNPs (Fig. 5C,D). In Bcl-
xL;Mcl-1dKO cerebella, fewer CGNPs survived to cell cycle exit, resulting in failure to 
generate a distinguishable IGL (Fig. 5E). The enhanced growth failure and accelerated 
apoptosis compared to Bcl-xLcKO mice, demonstrates that MCL-1 suppresses apoptosis 




Bcl-xLcKO CGNPs show increased SHH-driven proliferation, suggesting 
SUFU:MCL-1 interaction 
 MCL-1, BCL-xL and BCL2 have recently been reported to be positive regulators 
SHH signaling that act by inhibiting SUFU, which is a negative regulator of SHH124. In 
light of this report and our finding of dramatically increased MCL-1 protein in Bcl-xLcKO 
CGNPs, we examined whether Bcl-xLcKO CGNPs at P12 showed increased SHH 
activation compared to controls. Consistent with increased SHH activation, we found 
greater proportions of cells in the Bcl-xLcKO EGL expressing SHH target genes MATH1 
(aka ATOH1), and CCND1 (Fig. 6 A-D). Importantly, vismodegib blocked CGNP 
hyperproliferation in P12 Bcl-xLcKO mice, confirming that the observed hyperproliferation 
was driven by increased SHH signaling (Fig. 6E,F). Based on these data, we propose 
increased MCL-1 in Bcl-xLcKO CGNPs increases the mitogenic effect of endogenous 





 Our data show that neural progenitors continuously require anti-apoptotic BCL-xL 
to maintain their survival as they progress from proliferative undifferentiated cells to 
neurons. Conditional deletion of Bcl2l1 in the Math1 lineage in Bcl-xLcKO mice prevented 
BCL-xL expression in CGNPs and caused symptomatic cerebellar growth failure. This 
growth failure was caused by spontaneous apoptosis that occurred sporadically, at an 
increased rate compared to BCL-xL-intact controls. Proliferative CGNPs of the oEGL, 
non-proliferative CGNPs of the iEGL and CGNs of the IGL all showed increased 
apoptotic frequency. BCL-xL dependency was higher in non-proliferating cells, including 
differentiating CGNPs and CGNs, than in proliferating CGNPs, causing the IGL to be 
disproportionately depleted.  
In addition to increased cell death, we also noted an increased duration of CGNP 
proliferation. While most CGNPs typically exit the EGL by P12, in P12 Bcl-xLcKO mice 
the EGL remained abnormally thick and populated with proliferative cells. The increased 
EGL thickness at P12 contrasts with the thinning of the IGL that is apparent at this time. 
Thus the two aspects of the phenotype of Bcl-xLcKO mice were cerebellar hypoplasia 
that was apparent by P12 and was caused by excessive apoptosis, and persistent 
CGNP proliferation that ultimately waned by P15. Both of these aspects of the 
phenotype were BAX-dependent, as co-deletion of Bax in Bcl-xL;BaxdKO rescued both 
growth failure and prolonged proliferation. 
Our studies of MCL-1 demonstrated a mechanism for the relative preservation of 
proliferating CGNPs in Bcl-xLcKO mice. We found that proliferating CGNPs in S-G2/M 
phase consistently expressed MCL-1 protein while CGNPs in G0-G1 showed variable 
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MCL-1 expression. BCL-xL depletion in the Bcl-xLcKO mice further increased the 
abundance of MCL-1 protein in proliferating cells.  The cell cycle-dependent expression 
of MCL-1 protein and the increased MCL-1 in BCL-xL-deficient CGNPs suggested that 
MCL-1 could be the mechanism preserving the survival of proliferating CGNPs in Bcl-
xLcKO mice. This role was confirmed by co-deletion of Mcl-1 and Bcl2l1 in Bcl-xL;Mcl-
1dKO mice, which increased spontaneous apoptosis in the proliferating CGNPs and 
enhanced the cerebellar growth failure phenotype. Taken together, our data show that 
CGNPs depend on BCL-xL to prevent spontaneous apoptosis, and that MCL-1 provides 
a redundant brake on apoptosis specifically during proliferation. 
The increased expression of MCL-1 protein in CGNPs may also mediate the 
increased CGNP proliferation noted in P12 Bcl-xLcKO mice. Both BCL-xL and MCL-1 
have been shown to amplify SHH signaling by reducing the inhibitory effect of SUFU124. 
However, we found that MCL-1 abundance was linked to BCL-xL in CGNPs and 
increased 10-fold in the Bcl-xLcKO. We speculate that this increase in MCL-1 amplified 
the developmentally waning SHH pathway activity in P12 Bcl-xLcKO CGNPs.  Consistent 
with increased SHH signaling, we noted that P12 Bcl-xLcKO CGNPs showed increased 
expression of SHH targets MATH1 and CCND1. It was not possible to use genetic 
deletion to determine if MCL-1 mediated increased SHH signaling at P12, since 
proliferating CGNPs did not survive to P12 in Bcl-xL;Mcl-1dKO. However, the coincidence 
of increased MCL-1 and prolonged proliferation provides circumstantial evidence to 
support this mechanism. In light of these data, we propose that BCL-xL expression 
positively regulates CGNP differentiation by suppressing the abundance of MCL-1.  
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Our MCL-1 studies in CGNPs do not demonstrate the dependence seen in other 
models of Mcl-1 deletion in different parts of the nervous system. We found that CGNPs 
with Mcl-1 deletion were sensitized to Bcl2l1 haploinsufficiency but otherwise showed 
normal survival and development, indicating that BCL-xL and MCL-1 act in concert, with 
BCL-xL as the primary brake on CGNP apoptosis.  It remains possible that the 
requirement for Mcl-1 is greater in progenitors outside of the Math1 lineage, as seen in 
prior studies of cortical and SVZ progenitors109,111. However, our data make clear that 
MCL-1 is not required for all neural progenitors.  
Overall, our data show that anti-apoptotic BCL-2 proteins are required at all 
phases of neural progenitor maturation, but that the requirement for specific BCL-2 
family proteins varies with proliferative state. Functional redundancy during proliferation 
reduces the dependence of proliferating progenitors on individual BCL-2 family 
members. MCL-1 is not required during CGNP development because BCL-xL can meet 
the requirement of both proliferating and differentiating progenitors. In contrast, 
proliferating CGNPs show relatively less BCL-xL dependence because MCL-1 can 
partially compensate for BCL-xL depletion. This compensation is facilitated by a 
homeostatic mechanism that increases MCL-1 abundance in BCL-xL-depleted cells. 
The potentiating effect of MCL-1 on mitogenic SHH signaling further increases the 
tendency of surviving cells to be proliferative. Conversely differentiating CGNPs, which 
have lower MCL-1, are most dependent on BCL-xL. Through these mechanisms, the 
proximity of CGNPs to the apoptotic threshold is modulated as CGNPs progress 
through development to CGNs, while anti-apoptotic mechanisms provide regulatory 
feedback on the differentiation process.  
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2.5 Materials and Methods 
 
 Mice  
We generated Bcl-xLcKO mice by crossing Math1-Cre (Jackson Labs, stock 
#011104) and Bcl2l LoxP/LoxP 115 mouse lines. To generate the Bcl-xL;BaxdKO, Bax LoxP/LoxP 
mice were acquired as Bax LoxP/LoxP;Bak-/-  from Jackson Laboratories and selectively 
bred to replace both mutant Bak alleles with wild-type alleles. Co-deletion of Bcl2l and 
Bax was then accomplished by crossing Bax LoxP/LoxP mice into the Bcl-xLcKO line. To 
generate mice with Bcl-xL and Mcl-1 co-deletion (Bcl-xL;Mcl-1cKO) we bred Mcl-1LoxP/LoxP 
animals123 with the Bcl-xLcKO line. All experiments were conducted in accordance with 
the approval and guidelines of the University of North Carolina at Chapel Hill’s 
Institutional Animal Care and Use Committee (IACUC#13-121,16-099, 18-107). All mice 
for these experiments were of the species Mus musculus, maintained on the C57/BLK6 
background. The number of replicates in each experiment is specified in the figure 
legend and graphed as individual data points. All replicates represent individual mice 
and are thus biological replicates. Sample sizes were based on sample sizes adequate 
in prior published studies103,125,126. Genotypes were determined by PCR and presence 
or absence of BCL-xL protein was verified by immunohistochemistry. Mice of each 
genotype were randomly selected to include both males and females at postnatal days 





Histology and immunohistochemistry of cerebellar sections 
Mouse brain specimens were processed, sectioned and stained as previously 
described125,126 using primary antibodies: BCL-xL diluted 1:300 (Cell Signaling, #2764), 
phosphorylated RB (pRB) diluted 1:3000 (Cell Signaling, #8516), phosphorylated 
histone H3 (pHH3) diluted 1:100 (Cell Signaling, #9706), cleaved caspase-3 (cC3) 
diluted 1:50 (Cell Signaling, #9664), PCNA diluted 1:2000 (Cell Signaling, #2586), 
MATH1 (Aka ATOH1) diluted 1:200 (Abcam, #ab105497) and CyclinD1 (CCND1) 
diluted 1:500 (Cell Signaling, #2978). For immunofluorescence (IF), nuclei were 
counterstained with 4′6-diamino-2-phenylindole (DAPI; Thermo Fisher Scientific, 
#D1306), 200 ng/mL, for 20 minutes and immunoreactivity was evaluated with a Leica 
epifluorescence DM5000B microscope (Leica Microsystems). Stained slides were 
digitally acquired using an Aperio ScanScope XT (Aperio). For quantification, the EGL, 
IGL and whole cerebella were manually annotated on each section then subjected to 
automated cell counting using Tissue Studio (Definiens).  
 
CGNP isolation and flow cytometry  
CGNPs were isolated at P7 from WT or Bcl-xLcKO mice as previously 
described125 In brief, whole cerebella were dissected free of meninges, then dissociated 
in papain at 37C for 15 minutes and selected on a density gradient of ovomucoid 
inhibitor (Worthington Biochemical Corporation, #LK003150). Dissociated CGNPs were 
fixed, permeabilized and then stained. CGNPs were stained for DNA content using 
FxCycle Violet at 1:100 (Life Technologies, #F10347), for proliferation with 647-
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conjugated pRB antibodies diluted 1:50 (Cell Signaling, #89745) and for MCL-1 
expression with PE-conjugated MCL-1 antibodies diluted 1:50 (Cell Signaling, #65617). 
Cells were then analyzed using an LSRFortessa (BD Biosciences) at the UNC Flow 
Cytometry Core Facility. Flow cytometry data generated was analyzed using FlowJo 
v10 (FloJO, Becton Dickinson).  
 
POx-Vismo formulation  
The amphiphilic triblock copolymer poly(Methyl-Butyl-Methyl) oxazoline (POx), 
P(MeOx37-b-BuOx21-b-MeOx36), was synthesized as previously described127. 
Vismodegib-loaded polyoxazoline micelles (POx-Vismo) were prepared using the thin 
film hydration method128. Vismodegib (10mg/ml in acetone) was mixed with POx 
solution in acetone (2:10-8:10 drug to polymer w/w ratios). Following complete removal 
of acetone, the resulting thin film was rehydrated with saline at 60°C. Samples were 
allowed to cool to room temperature and then centrifuged at 10k RPM for 3 minutes to 
remove any non-loaded Vismodegib. Only the transparent supernatant solution was 
used for subsequent experiments. Micelle hydrodynamic diameter was determined by 
dynamic light scattering using a Malvern Nanosizer (Malvern Instruments Ltd). Final 
POx-Vismo concentration was 100 μg/mL, determined by HPLC.  
 
Vismodegib in vivo administration  
For in vivo studies, Bcl-xLcKO and control mice were injected IP with 100 mg/kg of 
POx-Vismodegib or an equal volume of saline control. Animals were injected at 24-hour 
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intervals for two consecutive days starting at P5 or P10. 24 hours after the last injection, 
animals were sacrificed and brains were harvested for IHC or flow cytometry.  
 
Western Blot 
Whole cerebella were homogenized in lysis buffer (Cell Signaling, #9803). 
Protein concentrations were quantified using the PierceTM BCA Protein Assay Kit 
(Thermo Fisher Scientific, #23225) and equal concentrations of protein were resolved 
on SDS-polyacrylamide gels then transferred to polyvinylidene difluoride membranes. 
Immunologic analysis was performed on a SNAP ID device (Millipore) using 
manufacturer’s protocol with primary antibodies to β-Actin at 1:5000 (Cell Signaling, 
#4970) and MCL-1 at 1:500 (Cell Signaling, #94296). Secondary antibodies were anti-
rabbit IgG HRP (Cell Signaling, #7074), and anti-mouse IgG HRP (Cell Signaling, 
#7076), both at 1:200. Western blots were developed using the enhanced 
chemiluminescent SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Fisher Scientific, #34095) digitized using the C-DiGit blot scanner (LI-COR), and 
quantification was performed using Image Studio Lite software (LI-COR). The western 
blot was repeated twice with similar results. 
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2.6 Figures and Legends  
 
Figure 1. Bcl-xLcKO mice show cerebellar hypoplasia and prolonged CGNP 
proliferation in the EGL. (A) Growth failure in Bcl-xLcKO mice shown in representative 
H&E stained sagittal brain sections from the indicated age and genotype. (B) IHC for 
BCL-xL in representative sagittal cerebellar sections from the indicated genotype, 
counterstained blue with hematoxylin, demonstrate absence of BCL-xL protein in Bcl-
xLcKO mice. (C,D) Representative pRB IF in sagittal cerebellar sections from P12 Bcl-
xLcKO and control mice, with quantification of %pRB+ cells in the EGL from indicated 
genotypes, demonstrate increased EGL thickness and pRB expression in Bcl-xLcKO 
cerebella. (E,F) Representative pHH3 IHC in sagittal cerebellar sections from P12 Bcl-
xLcKO and control mice, with quantification of %pHH3+ cells in the EGL from indicated 
genotypes, demonstrate increased mitoses in Bcl-xLcKO cerebella. Arrows indicate the 
IGL, EGL, oEGL and iEGL regions. Black curved line in (A,B) indicates the posterior-
inferior folia that are preserved in the Bcl-xLcKO mice. Size markers indicate 1mm in low 
magnification images and 500 µm in high magnification images, except for (B) which is 
50 µm. Nuclei are counterstained with hematoxylin in IHC images and with DAPI in IF 






Figure 2. Increased apoptosis in Bcl-xLcKO mice is rescued by co-deletion of Bax. 
(A,B) Representative cC3 IHC in sagittal cerebellar sections from P7 Bcl-xLcKO , Bcl-
xL;BaxdKO and control mice, with quantification of %cC3+ cells in the EGL and IGL from 
indicated genotypes, demonstrate increased apoptosis at P7 in Bcl-xLcKO cerebella. 
(D,E) Representative IHC for cC3 in sagittal cerebellar sections from P12 Bcl-xLcKO , 
Bcl-xL;BaxdKO and control mice, with quantification of %cC3+ cells in the whole cerebella 
from indicated genotypes demonstrate increased apoptosis at P12 in Bcl-xLcKO and Bcl-
xL;BaxdKO cerebella. (F,G) Representative pRB IF images of sagittal cerebellar sections 
at P12 from Bcl-xL/BaxdKO mice, with quantification of %pRB+ cells in the EGL from 
indicated genotypes, shows normalization of CGNP proliferation at P12 in Bcl-xL/BaxdKO 
cerebella. In 2G, control mice from 1D are presented for comparison. Arrows indicate 
the EGL and IGL regions. Size markers indicate 1mm in low magnification images and 
500 µm in high magnification images. Nuclei are counterstained with hematoxylin in IHC 







Figure 3. Apoptosis in Bcl-xLcKO CGNPs is linked to cell-cycle exit.                       
(A) Representative PCNA/cC3 IF in sagittal cerebellar sections from P7 Bcl-xLcKO , Bcl-
xL;BaxdKO and control mice, with (B) quantification of the %cC3+ cells in the PCNA+ 
oEGL and PCNA- iEGL, and (C) log ratio of apoptotic rate iEGL:oEGL, for the indicated 
genotypes. (D,E) Representative dot plots pRB IF versus DNA content, measured by 
flow cytometry, in Bcl-xLcKO and control CGNPs, with quantification of pRB+ cells in 
dissociated CGNPs of the indicated genotypes. (F,G) Representative PCNA IF in 
sagittal cerebellar sections from P7 Bcl-xLcKO  and control mice treated with either 
vehicle or vismodegib at P5 and P6, with quantification of %PCNA+ cells in whole 
cerebellar sections from indicated genotypes and treatments, demonstrate that 
vismodegib reduces PCNA in both genotypes. (H, I) Quantification of (H) cell density 
and (I) density of PCNA+ cells  in the EGL from indicated genotypes and treatments, 
shows vismodegib reduces total cell population and PCNA+ population more effectively 
in Bcl-xLcKO mice. Arrows indicate the IGL, EGL, oEGL and iEGL regions. Size markers 
indicate 1mm in low magnification images and 500 µm in high magnification images. All 
IF images are counterstained with DAPI. P values in (B, C, E, G) determined by two-








Figure 4. MCL-1 is more abundant in proliferating CGNPs and is markedly 
increased in Bcl-xLcKO mice. (A,B) Representative dot plots of MCL-1 IF versus DNA 
content, measured by flow cytometry and stratified into G0/G1, S and G2/M fractions, 
with quantification of MCL-1 MFI in G0/G1, S -G2/M phases. (C,D) Representative dot 
plots as in (A), comparing MCL-1 in CGNPs of P7 Bcl-xLcKO and control mice, with 
quantification of MCL-1 MFI in CGNPs from the indicated genotypes. (E,F) 
Representative western blots comparing the abundance of MCL-1 protein in lysates of 
whole cerebella of P7 Bcl-xLcKO and control mice, with quantification of MCL-1 
abundance normalized to -actin. Dot plots indicate data from individual replicate mice 
and horizontal bars with error bars indicate the mean +/-SEM. P values determined by 







Figure 5. MCL-1 compensates for BCL-xL in proliferating CGNPs.                          
(A) Representative sagittal H&E-stained sections comparing of cerebella from P16 Bcl-
xlHET, and MCL-1cKO and Bcl-xLHET/Mcl-1cKO mice (B) Representative sagittal H&E-
stained section of a Bcl-xL/Mcl-1dKO cerebellum at P7 and P16. (C,D) Representative 
PCNA/cC3 IF in sagittal cerebellar sections from P7 Bcl-xL/Mcl-1dKO , with quantification 
of the %cC3+ cells in the PCNA+ oEGL and PCNA- iEGL from the indicated genotypes. 
(E) Representative PCNA/p27 IF in sagittal sections of P7 Bcl-xL/Mcl-1dKO and WT 
control cerebella. In 5D, Bcl-xLcKO and control mice from 3B are presented for 
comparison. Size markers indicate 1mm in low magnification images and 500 µm in 
high magnification images All IF images are counterstained with DAPI. P values 








Figure 6. Prolonged CGNP proliferation in P12 Bcl-xLcKO mice is due to increased 
SHH activation. (A-D) Representative (A) MATH1 and (B) CCND1 IF in sagittal 
cerebellar sections from P12 Bcl-xLcKO and control mice, with quantification of (C) 
MATH1+ cells or (D) CCND1+ cells per 200 µm length of EGL in the indicated 
genotypes. (E,F) Representative pRB IF in sagittal cerebellar sections from P12 Bcl-
xLcKO and control mice, with quantification of %pRB+ cells in the EGL in the indicated 
genotypes. Size markers indicate 1mm in low magnification images and 500 µm in high 
magnification images All IF images are counterstained with DAPI. P values determined 











CHAPTER THREE: BCL-XL DELETION PLAYS A DUAL ROLE IN 




Medulloblastoma is uniquely sensitive to radiation therapy which confers a 70-
80% survival rate, at the expense of severe neurocognitive and social deficits. 
Understanding the mechanisms responsible for medulloblastoma sensitivity to 
conventional radiation may identify less toxic ways to achieve a similar or greater 
therapeutic effect. We have previously shown that the radiation sensitivity of SHH-
driven medulloblastomas depends on the function of the intrinsic apoptosis pathway.  
Here we tested whether this pathway could be activated directly, without radiation, by 
disrupting the anti-apoptotic protein BCL-xL. 
 We analyzed the neuropathology and survival of medulloblastoma-bearing mice 
with tumor-specific deletion of Bcl2l1, the gene that encodes BCL-xL. Tumors in these 
mice showed focal regions of necrosis. The mice showed significantly longer survival 
than medulloblastoma-bearing littermates with intact Bcl2l1, but inevitably died of 
progressive disease. Further analysis of Bcl-xL-deleted tumors showed increased 
fractions of tumor cells expressing proliferation markers suggesting that increased 
proliferation and decreased differentiation may allow tumors to evade BCL-xL 
dependence and continue to grow. Consistent with this interpretation, expression 
microarray analysis showed up-regulation of the cell cycle regulators Cdk2, Cdc4 and 
down-regulation of differentiation markers in Bcl-xL-deleted tumors. Microarray analysis 
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also showed an increase in tumor associated macrophages in Bcl-xL-deleted tumors, 
which may contribute to the Bcl-xL deletion phenotype. We also found that MCL-1 
expression in proliferating MB cells is regulated by SHH signaling and can potentially 
compensate for loss of Bcl-xL. All together our data suggest that blocking SHH-induced 
proliferation and targeting the intrinsic apoptosis pathway may synergize in 





Medulloblastoma, the most prevalent pediatric brain tumor, is distinct among 
malignant brain tumors in being typically sensitive to radiation therapy. However, 
medulloblastoma survivors treated with radiation suffer long-term treatment-induced 
toxicities. These include impairments in motor, neuroendocrine and cognitive functions 
that are accompanied by high rates of unemployment and academic failure\129. New 
approaches are needed to reduce damaging side effects of medulloblastoma treatment, 
and therapies that target apoptosis regulation may be particularly effective for this 
heterogeneous disease.  
Medulloblastoma comprises four molecularly distinct subgroups: WNT, SHH, 
Group 3, and Group 4130,131. Prognosis varies both between and within subgroups and 
is affected by genetic alterations and age at onset, but overall, medulloblastoma tends 
to respond to surgical tumor resection followed by radiation and chemotherapy, with 
80% of patients receiving this treatment surviving >8 years 132,133. Tumors classified in 
the SHH subgroup arise from hyper-activation of SHH signaling through diverse 
mechanisms including germline and somatic mutations, and together make up 
approximately 30% of total medulloblastoma cases. Typical mutations include loss-of-
function mutations or deletions in PTCH1 or SUFU, amplification of Gl1, GLI2 or MYCN 
or SMO activating mutations82,83. These alterations all lead to constitutive activation of 
SHH signaling, causing overexpression of downstream genes targets that drive cell 
growth and proliferation.  
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The phenotype of SHH-subgroup medulloblastoma can be recapitulated in mice 
with activating SHH pathway mutations134–136. Here, we use transgenic SmoM2 mice137 
that express a mutant, constitutively active allele of Smoothened (Smo) under the Math-
1;Cre promoter113. Smo activation induces expression of GLI transcription factors that 
promote proliferation in cerebellar granule neuron progenitors and leads to 
medulloblastoma formation with 100% frequency by P12138. SHH activation of Math-
1;Cre-SmoM2 with additional genetic deletion of apoptotic genes of interest generates 
models that may show how individual genes contribute to normal tumor formation and 
tumor responses to conventional therapies.  
Mutations in p53 increase the frequency of medulloblastoma in mice139 and 
humans140,141, suggesting a potential role for apoptosis in suppressing medulloblastoma 
formation. However the contributions of more proximal apoptotic regulators to tumor 
formation and therapy response remains largely unknown. Our previous findings show 
CGNPs, the cells of origin for SHH-driven medulloblastoma, maintain the pro-apoptotic 
protein BAX in its activated conformation bound with BCL-xL to prevent spontaneous 
apoptosis142, and that BAX is required for the sensitivity of tumors to cell death 
mediated by radiation therapy142 or the BH-3 mimetic ABT-737103. Based on these prior 
observations, we hypothesized that selectively targeting BCL-xL would yield similar 
effects in promoting tumor cell death and could prove to be a potential therapeutic 
target. To test this hypothesis and to identify potential mechanisms of therapeutic 
resistance, we analyzed the effect of conditional Bcl2l1 deletion in of Math-1;Cre-
SmoM2 mice. 
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3.3 Results  
 
Bcl2l1 is expressed in SHH-driven medulloblastoma model and deletion provides 
mild survival benefit 
Based on our findings of BCL-xL dependence in CGNPs, the cells of origin for 
SHH-driven medulloblastoma, we hypothesized that medulloblastomas would similarly 
show BCL-xL dependence. To test this hypothesis, we investigated whether selectively 
targeting BCL-xL in medulloblastoma would increase tumor cell death and slow tumor 
progression. Using IHC we confirmed ubiquitous BCL-xL expression in tumors of P15 
Math-1Cre;SmoM2loxP/loxP (Math-1Cre;SmoM2) mice (Fig. 1A). To determine if MB cells 
require BCL-xL to survive, we generated mice with Bcl2l1-deleted tumors by breeding 
Bcl-xLcKO and SmoM2  mouse lines to produce Math1-Cre;Smom2 loxP/+;Bcl2l1 loxP/+ 
(Math1-Cre;SmoM2;Bcl-xLHET) and Math1-Cre;SmoM2 loxP/+;Bcl2l1 loxP/loxP (Math1-
Cre;SmoM2;Bcl-xLcKO) mice. Math1-Cre;Smom2;Bcl-xLcKO tumors at P15 showed areas 
of focal necrosis and acellularity that were visible in H&E sections and were not found in 
control tumors, suggesting increased apoptosis (Fig. 1A).  
 To determine the therapeutic potential of BCL-xL disruption, we measured the 
event free survival (EFS) of Math1-Cre;SmoM2;Bcl-xLHET and Math1-Cre;SmoM2;Bcl-
xLcKO  mice compared to historical Math-1Cre;SmoM2142 controls (Fig. 1B). Deletion of 
Bcl-xL significantly increased the median survival time to 33 days in Math1-
Cre;SmoM2;Bcl-xLcKO mice. We noted no statistical difference between Math1-
Cre;SmoM2;Bcl-xLHET and Math-1Cre;SmoM2 groups, therefore both are used as 
experimental controls. While Bcl-xL deletion significantly extended mouse survival, this 
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effect was not curative. All mice died by 87d, indicating consistent tumor recurrence and 
suggesting development of resistance to BCL-xL disruption.  
 
Math1-Cre;Smom2;Bcl-xLcKO tumors show increased apoptosis, but Bcl-xL- 
deleted cells remain present  
To understand mechanisms of both potential therapeutic effect and recurrence, 
we tested whether Bcl-xL deletion increased apoptosis at P12 and P20. Apoptosis was 
measured counting cC3+ cells in tumor sections from Math1-Cre;SmoM2;Bcl-xLcKO and 
Math1-Cre;SmoM2;Bcl-xLHET mice(Fig. 2A). In line with our hypothesis, we noted 
significantly higher percentages of cC3+ cells in Math1-Cre;SmoM2;Bcl-xLcKO tumors at 
P12. The relative increase in apoptosis in Math1-Cre;SmoM2;Bcl-xLcKO versus Math1-
Cre;SmoM2;Bcl-xLHET was less at P20 than at P12, and was no longer statistically 
significant, suggesting that the pro-apoptotic effect of Bcl2l1 deletion wanes over time 
(Fig. 2B). 
We previously found Bcl-xL-deleted CGNPs have a higher rate of apoptosis in 
both proliferating and newly differentiated neurons, but CGNPs that have exited the cell 
cycle are more susceptible and can be delineated by the absence of PCNA (Chapter 2, 
Fig. 3). To analyze cell death in proliferating and non-proliferating tumor cells, we 
compared co-expression of cC3 and PCNA in Math1-Cre;SmoM2;Bcl-xLcKO and Math1-
Cre;SmoM2;Bcl-xLHET  tumors at P12 (Fig. 2C,D). As in CGNPs, we found increased 
apoptosis in Math1-Cre;SmoM2;Bcl-xLcKO tumors in both PCNA+ and PCNA- cell 
populations, with the largest increase in the PCNA- MB cells. These findings 
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demonstrate that like CGNPs, MB cells depend on BCL-xL for survival before and after 
cell cycle exit, and that differentiation increases this dependence. 
 We also noted, despite increased apoptosis, that most cells within Bcl-xL-
deleted tumors were BCL-xL- at both P12 and P20, demonstrating that recurrence was 
not driven by tumor cells that escaped Bcl-xL deletion (Fig. 2E). Rather, these findings 
indicate a protective mechanism prevents cell death in Bcl-xL-deficient MB cells that 
survive. Based on our findings in CGNPs we propose Bcl-xL-deleted tumor cells may 
remain in the proliferative state to escape heightened cell death, rely on other BCL-2 
family members for survival, or a combination of both.  
 
Persistent proliferation contributes to recurrence in Bcl-xL-deleted tumors  
Our studies in the Bcl-xLcKO cerebellum identified a reciprocal interaction in which 
SHH-driven proliferation preserves Bcl-xL-deleted cells and Bcl-xL deletion potentiates 
the mitogenic effect of SHH signaling, lengthening the period of post-natal proliferation. 
We examined if similar reciprocal mechanisms contribute to tumor recurrence in Bcl-xL-
deleted MB tumors by analyzing changes in proliferation over time in P12 and P20 
SmoM2 control (Math1-Cre;SmoM2 or Math1-Cre;SmoM2;Bcl-xLHET ) and Math1-
Cre;SmoM2;Bcl-xLcKO mice. Comparing expression of the mitotic marker pHH3 in 
sagittal tumor sections, we found a significantly higher percentage of pHH3+ nuclei in 
Math1-Cre;SmoM2;Bcl-xLcKO tumors at P12 and P20 (Fig. 3A,B). Likewise, flow 
cytometry studies showed that at P12 the pRB+ fraction of cells was larger in Math1-
Cre;SmoM2;Bcl-xLcKO tumors (Fig. 3C,D), specifically within the G1 population. 
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Increased expression of pRB continued through P20 (Fig. 3E,F). The increases in pHH3 
and pRB in Bcl-xL-deleted tumors confirm increased proliferation, which may reduce 
BCL-xL dependence, allowing continued tumor growth.  
 
MCL-1 is regulated by SHH in medulloblastoma model 
In the developing cerebellum MCL-1 compensates for loss of BCL-xL, protecting 
Bcl-xL-deleted CGNPs during proliferation (Chapter 2, Fig. 4). To determine if 
medulloblastoma cells in our model express MCL-1, we analyzed MCL-1 protein 
expression by flow cytometry. To determine if MCL-1 correlates with SHH-driven 
proliferation in medulloblastoma as we found in CGNPs, we administered vismodegib at 
P10 and P11 (2x Vismodegib) to Math1-Cre;SmoM2 mice and compared to saline-
injected controls (No Drug), both harvested for flow cytometry and IHC. Reduced pRB 
staining in Math1-Cre;SmoM2 tumor sections demonstrated that vismodegib blocked 
SHH-driven proliferation (Fig. 4A). Flow cytometry confirmed these findings, showing a 
significant depletion of pRB+ cells in dissociated Math1-Cre;SmoM2 tumors from 
vismodegib treated mice (Fig. 4B,C,D).  
We also noted that MCL-1 expression in dissociated MB tumors varied across 
the cell cycle. At G0/G1 dissociated tumors showed a range of MCL-1+ and MCl-1- 
expression, while MB tumor cells in S-G2/M were consistently MCL-1+. This pattern 
suggested that MCL-1 could reduce BCL-xL dependence in proliferating cells in Math1-
Cre;SmoM2;Bcl-xLcKO tumors as in Bcl-xLcKO CGNPs (Fig. 4E). Blocking SHH-driven 
proliferation significantly reduced MCL-1 levels (Fig. 4F,G), providing more support that 
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MCl-1 expression is linked to proliferation status of MB cells Preliminary data suggest 
that Math1-Cre;SmoM2;Bcl-xLcKO tumors increased MCL-1 protein levels (Fig. 4H). We 
will seek to validate this finding in replicate flow cytometry and western blot studies of 
MCL-1. Together, these data show that MCL-1 protein levels are regulated by SHH 
signaling and cell cycle progression and suggest that MCL-1 increases in the absence 
of BCL-xL. Further, these data suggest SHH-dependent MCL-1 limits apoptosis in the 
absence of BCL-xL and that combined targeting of BCL-xL and SHH signaling may be 
advantageous in MB therapy.   
 
Differential gene expression analysis supports increased proliferation as a 
mechanism of resistance and reveals a role for TAMs 
To understand the cell biological events set in motion by BCL-xL disruption in 
tumors, we compared gene expression in P15 Math1-Cre;SmoM2;Bcl-xLcKO and Math1-
Cre;SmoM2 tumors using expression microarrays. We found that 188 genes were 
differentially expressed with cutoffs of false discovery rate (FDR) p≤0.001 and Log2 fold 
change (FC) ≥1.5 (Fig. 5A, Table 1). Of those genes, we found 149 were significantly 
upregulated and 39 were significantly downregulated, including Bcl2l1. To account for 
tumor cell heterogeneity in our analysis and to determine the cells of origin responsible 
for expression changes,  we compared the top hits from our microarray to our database 
of single-cell RNA-seq data from P15 M1-Cre;SmoM2 mice (Table 2). We used these 
comparisons to identify genes of interest by their cellular expression patterns.  
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Within this data, we noted upregulation of two genes that are typically expressed 
in proliferating tumor cells and are associated with increased cell cycle progression: Cell 
division cycle associated 4 (Cdca4, FDR=5.95E-06, Log2FC=1.67) and Cyclin-
dependent kinase 2 (Cdk2, FDR=1.28E-04, Log2FC=1.57) (Fig. 5 B,C). CDCA4 is 
reported to be a transcriptional target of E2F transcription factors143 , consistent with our 
observation of increased pRB in the Math1-Cre;SmoM2;Bcl-xLcKO  tumors and CDK2 
advances the cell cycle at the G1-S transition144. In our single-cell RNA-seq data both 
genes are highly expressed in proliferative cells in Math1-Cre;SmoM2 tumors (Fig 5B).  
In contrast to these up-regulated proliferation markers, we also noted down-regulation 
of differentiation markers including, Transthyretin (Ttr, FDR=2.11E-06, Log2FC=-35.19) 
and Contactin 2 (Cntn2, FDR=3.62E-05, Log2FC=-2.29) (Table 2). Alongside the up-
regulation of cell cycle genes, the down-regulation of differentiation genes supports the 
hypothesis that absence of BCL-xL in SHH-driven medulloblastoma selects for tumor 
cells that re-enter the cell cycle. 
Among the differentially expressed genes, we also noted that the stem cell 
marker CD44145 was up-regulated in Math1-Cre;SmoM2;Bcl-xLcKO  (FDR=2.75E-04, 
Log2FC=1.78) (Table 1). This finding may be of significance because CD44+ cells were 
particularly sensitive to vismodegib in our prior study146 (Fig. 5D). We also noted 
upregulation in Math1-Cre;SmoM2;Bcl-xLcKO   tumors of two putative p53 suppressors 
RUN Domain Containing-1 (Rundc1, FDR=4.19E-04, Log2FC=1.56)  and Ribosomal 
Protein S6 Kinase A1 (Rps6ka, FDR=2.96E-04, Log2FC=1.56) (Table1, Table2). 
Rundc1 and Rps6ka overexpression in human osteosarcoma cells reduces p53 
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mediated apoptosis 147, and the up-regulation of these genes may identify p53 
disruption as a mechanism of cell survival in Bcl-xL-deleted tumors.  
Lastly, we noted an increase in numerous genes associated with macrophages, 
microglia, and altered immune response in Math1-Cre;SmoM2;Bcl-xLcKO  tumors. 
Comparison to our single-cell RNA-seq data showed that of the top 15 genes with the 
lowest p-values, 8 were expressed by microglia in Math1-Cre;SmoM2 tumors (Table 1 
and Table 2). Tumor necrosis factor (Tnf) was the most highly expressed (FDR=9.83E-
07, Log2FC=2.11) and encodes a proinflammatory cytokine that participates in a wide 
spectrum of signaling pathways including apoptosis, cell survival and proliferation148–151. 
Recent studies suggest in vivo treatment with TNF can sensitize p53-mutuant 
medulloblastomas to immunotherapy152,153, however the role of TNF in SHH-driven 
medulloblastoma is unknown.  
The increased expression of cytokines in our data highlight the importance for 
understanding the role of the tumor microenvironment in regulating the growth and 
maintenance of MB tumors. Tumor-associated macrophages (TAMs) have been shown 
to have anti-tumoral effects in SHH-driven medulloblastoma154. Thus, we directly 
investigated if up-regulation of macrophage and microglial markers correlated with an 
increase TAMs in Math1-Cre;SmoM2;Bcl-xLcKO  tumors and if TAM population changed 
over the course of tumor progression. We compared expression of the TAM marker 
IBA1 in sagittal tumor sections of P12 and P20 Math1-Cre;SmoM2;Bcl-xLcKO and 
Math1-Cre;SmoM2;Bcl-xLHET mice. At P12, IBA1+ cells were clearly localized to areas 
of tumor necrosis in Math1-Cre;SmoM2;Bcl-xLcKO  tumors, and dispersed throughout the 
tumor by P20 when apoptosis wanes (Figure 6A). We found a higher percentage of 
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IBA1+ TAMs in Math1-Cre;SmoM2;Bcl-xLcKO tumors that was significant at P12 and 
trending towards significance at P20, consistent with increased gene expression (Fig. 
6B). These results suggest that TAMs may contribute an anti-tumor effect that results in 
increased survival of Math1-Cre;SmoM2;Bcl-xLcKO mice but is not strong enough to 
overcome the pro-tumor effect of increased proliferation seen in the absence of BCL-xL. 
All together our gene expression data support the hypothesis that increased 
proliferation in Math1-Cre;SmoM2;Bcl-xLcKO tumors leads to tumor recurrence and 





Our data show that disrupting BCL-xL function through genetic deletion in 
medulloblastoma increases the rate of spontaneous apoptosis by activating the intrinsic 
apoptosis pathway. Total apoptosis was initially increased in Math1-Cre;SmoM2;Bcl-
xLcKO  tumors compared to controls at P12, and conditional deletion of Bcl-xL in  Math1-
Cre;SmoM2;Bcl-xLcKO mice increased animal survival. However, tumors consistently 
adapted to BCL-xL deficiency and recurred, causing all tumor-bearing, Bcl-xL-deleted 
mice to die by age 87d. We show both PCNA+ and PCNA- tumor cells were sensitive to 
Bcl-xL deletion, although PCNA- MB cells were more susceptible to cell death, 
consistent with our findings in CGNPs. By P20 however, differences in apoptosis were 
no longer significant, suggesting that the pro-apoptotic effect of Bcl2l1 deletion 
decreases over time. This suggestion was confirmed by the persistence of Bcl-xL-
deleted cells in Math1-Cre;SmoM2;Bcl-xLcKO tumors at both P12 and P20, indicating the 
presence of Bcl-xL-independent tumor cells that under selective pressure lead to 
recurrence.  
Based on our previous findings in CGNPs, we propose tumor cells maintain BCL-
xL-independence by remaining in the proliferative state, by reliance on MCL-1 for 
survival, or a combination of both mechanisms. Consistent with our hypothesis, we 
found that Bcl-xL deleted tumors upregulate proliferation. Math1-Cre;SmoM2;Bcl-xLcKO  
tumors had higher fractions of cells expressing markers of mitosis (pHH3) and cell cycle 
progression (pRB) and both P12 and P20. Our hypothesis was also confirmed by our 
differential gene expression analysis comparing P15 Math1-Cre;SmoM2 and Math1-
Cre;SmoM2;Bcl-xLcKO tumors. We found Math1-Cre;SmoM2;Bcl-xLcKO tumors 
 70 
upregulate Cdca4 and Cdk2, genes associated with increased cell cycle progression, 
and down regulate genes associated with differentiation. Together these results provide 
evidence that Bcl-xL-deleted tumors adapt to maintain cell survival through upregulation 
of proliferation.  Increased MCL-1 expression in Math1-Cre;SmoM2;Bcl-xLcKO tumors 
may operate in parallel with increased proliferation, and may, though direct action on 
SHH-signaling, contribute to the proliferation increase.  
BCL-xL and MCL-1 have both been implicated in reducing the inhibitory effect of 
SUFU, leading to amplified SHH signaling124. We have previously shown that MCL-1 
maintains proliferating CGNPs when Bcl-xL is deleted, and potentiates the duration of 
SHH-dependent proliferation. In medulloblastoma, we show MCL-1 follows a similar 
pattern as MCL-1 was consistently expressed in MB tumor cells in S-G2/M phases of the 
cell cycle. Moreover, MCL-1 abundance decreased in tumors when SHH-driven 
proliferation was blocked with vismodegib. These findings show MCL-1 expression 
remains connected to proliferation status, even as proliferation is blocked. Based on this 
finding, SHH inhibition through vismodegib may decrease MCL-1 expression and 
sensitize MB tumor cells to BCL-xL disruption, proving to be a useful dual treatment 
regimen.   
Recent in vitro studies of human-derived MB cells show a synergistic approach of 
blocking SHH and MCL-1133, but they do not determine the role of other Bcl-2 family 
members, and the question remains if MB cells in this context develop resistance by 
upregulating BCL-xL. Thus, future studies are needed to verify the long-term potential of 
synergistic treatment targeting SHH-signaling and BCL-xL, and to determine if targeting 
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BCL-xL alone makes tumors more sensitive to conventional radiation and 
chemotherapy treatments.  
In addition to understanding the potential role of BCL-xL targeting in sensitizing 
tumors to conventional therapy, the interplay between BCL-xL mediated apoptosis and 
alterations in the tumor microenvironment, highlighted by the increase in TAMs, remain 
of interest. Primary patient tumor samples show increased expression of inflammation 
related genes and TAMs in the SHH subgroup of medulloblastoma155. While TAMs are 
markers of poor prognosis in many cancers156–158, the role of TAMs in SHH 
medulloblastoma not well characterized. 
One recent study shows higher expression of AIF1, the gene that encodes 
macrophage marker IBA1, was associated with increased survival in SHH-subgroup 
patients, and showed in vivo anti-tumoral effects of TAMs in MB154. We found that 
deletion of Bcl-xL in SHH-driven tumors increased the TAM abundance. Math1-
Cre;SmoM2;Bcl-xLcKO tumors upregulated numerous genes associated with microglia 
and macrophages compared to Math1-Cre;SmoM2 tumors, and this pattern 
corresponds to an increased number of IBA1+ TAMs in tumor sections at P12 and P20. 
While these TAMs may have localized anti-tumoral effects, Math1-Cre;SmoM2;Bcl-
xLcKO tumors eventually recur predominantly through upregulation of proliferation. 
Follow up studies are needed to determine if increased TAMs in Math1-Cre;SmoM2;Bcl-
xLcKO tumors contribute to recurrence. Studies with small molecule inhibitors or genetic 
deletion may help to discern these possibilities.  
Overall, our data show that anti-apoptotic BCL-xL is required by MB cells for 
survival and that deletion of Bcl-xL in SHH-driven medulloblastoma results in both 
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increased apoptosis and tumor cell proliferation. Tumor cells bypass BCL-xL 
dependence by remaining in a proliferative state which may be mediated by MCL-1.  
This mechanism is consistent with our findings in CGNPs, and shows the conservation 
of apoptotic function in medulloblastoma. Decreasing MCL-1 expression and cellular 
proliferation through blockage of SHH signaling in tandem with targeting of BCL-xL may 
prove to be a beneficial therapeutic intervention that when combined, overcomes the 
resistance of each single treatment. 
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3.5 Materials and Methods 
 
Mice  
We generated Math1-Cre; Bcl21 LoxP/LoxP (Bcl-xLcKO) mice by crossing Math1-Cre 
(Jackson Labs, stock #011104) and Bcl21 LoxP/LoxP 115 mouse lines. To generate 
medulloblastoma-prone animals with and without Bcl-xL deletion, first Bcl21 LoxP/LoxP 
mice were crossed with SmoM2loxP/loxP mice137,138 to generate SmoM2loxP/+;Bcl2l1loxP/+. 
The resulting SmoM2loxP/+;Bcl2l1loxP/+ mice were bred with Bcl-xLcKO  mice making both 
Math1-Cre;SmoM2 loxP/+;Bcl2l1 loxP/+ (Math1-Cre;SmoM2;Bcl-xLHET) and Math1-
Cre;SmoM2 loxP/+;Bcl2l1 loxP/loxP (Math1-Cre;SmoM2;Bcl-xLcKO),  in which tumorigenesis 
is induced by deletion of a loxP-flanked Stop cassette between the promoter and coding 
region of constitutively active mutant Smo138. Control tumor-bearing mice with intact 
Bcl2l1 used for IHC and flow cytometry were made by crossing Math1-Cre mice with 
SmoM2loxP/loxP mice (Math1-Cre;SmoM2). 
 All experiments were conducted in accordance with the approval and guidelines 
of the University of North Carolina at Chapel Hill’s Institutional Animal Care and Use 
Committee (IACUC#13-121,16-099, 18-107). All mice for these experiments were of the 
species Mus musculus, maintained on the C57/BLK6 background. The number of 
replicates in each experiment is specified in the figure legend and graphed as individual 
data points. All replicates represent individual mice and are thus biological replicates, 
unless otherwise indicated in figure legend. Sample sizes were based on sample sizes 
adequate in prior published studies103,125,126. Genotypes were determined by PCR and 
presence or absence of BCL-xL protein was verified by immunohistochemistry and mice 
of each genotype were randomly selected to include both males and females.   
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Kaplan Meier survival analysis 
Tumor-bearing mice were monitored daily for health status and movement 
abnormalities and mice were euthanized at the onset of symptoms, including 10% 
weight loss, ataxia or lethargy. The age of the animal at the time of harvest due to tumor 
symptoms was recorded as the event-free survival. The Kaplan-Meier method was used 
to estimate survival and Log Rank tests were used to compare survival between Math1-
Cre;SmoM2;Bcl-xLcKO (n=18), Math1-Cre;SmoM2;Bcl-xLHET (n=19), and Math1-
Cre;SmoM2 (n=12) experimental groups. Historical controls from our previous studies 
were used for the Math1-Cre;SmoM2 experimental group142. 
 
Histology and immunohistochemistry of tumor sections  
Mouse brain specimens were processed, sectioned and stained as previously 
described125,126 using primary antibodies: BCL-xL diluted 1:300 (Cell Signaling, #2764), 
phosphorylated RB (pRB) diluted 1:3000 (Cell Signaling, #8516), phosphorylated 
histone H3 (pHH3) diluted 1:100 (Cell Signaling, #9706), cleaved caspase-3 (cC3) 
diluted 1:50 (Cell Signaling, #9664), proliferating cell nuclear antigen (PCNA) diluted 
1:2000 (Cell Signaling, #2586), and ionized calcium-binding adapter molecule 1 (IBA11) 
diluted 1:2000 (Wako Chemicals, #019-19741). For immunofluorescence (IF), nuclei 
were counterstained with 4′6-diamino-2-phenylindole (DAPI; Thermo Fisher Scientific, 
#D1306), 200 ng/mL, for 20 minutes and immunoreactivity was evaluated with a Leica 
epifluorescence DM5000B microscope (Leica Microsystems). Stained slides were 
digitally acquired using an Aperio ScanScope XT (Aperio). For quantification tumors 
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were manually annotated on each section then subjected to automated cell counting 
using Tissue Studio (Definiens).  
 
Tumor cell isolation and flow cytometry  
Tumors were isolated at P12 from Math1-Cre;SmoM2,  Math1-Cre;SmoM2;Bcl-
xLHET or Math1-Cre;SmoM2;Bcl-xLcKO  or mice as previously described125,159. In brief, 
tumors were dissected free of meninges, dissociated in papain at 37C for 15 minutes 
and selected on a density gradient of ovomucoid inhibitor (Worthington Biochemical 
Corporation, #LK003150). Dissociated tumor cells were resuspended in HBSS 
supplemented with 6g/L glucose, fixed, permeabilized and then stained. Tumor cells 
were stained for DNA content using FxCycle Violet at 1:100 (Life Technologies, 
#F10347), for proliferation with 647-conjugated pRB antibodies diluted 1:50 (Cell 
Signaling, #89745) and for MCL-1 expression with PE-conjugated MCL-1 antibodies 
diluted 1:50 (Cell Signaling, #65617). Cells were then analyzed using an LSRFortessa 
(BD Biosciences) at the UNC Flow Cytometry Core Facility. Flow cytometry data 
generated was analyzed using FlowJo v10 (FloJO, Becton Dickinson).  
 
POx-Vismo formulation  
The Vismodegib loaded amphiphilic triblock copolymer poly(Methyl-Butyl-Methyl) 
oxazoline (POx), P(MeOx37-b-BuOx21-b-MeOx36), was synthesized described in 
Chapter 2 of this dissertation.  
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Vismodegib in vivo administration  
For in vivo studies, Math1-Cre;SmoM2, Math1-Cre;SmoM2;Bcl-xLHET and Math1-
Cre;SmoM2;Bcl-xLcKO mice were injected IP with 100 mg/kg of POx-Vismodegib or an 
equal volume of saline control. Animals were injected at 24-hour intervals for two 
consecutive days starting at P10. 24 hours after the last injection, animals were 
sacrificed and brains were harvested for IHC or flow cytometry. 
 
Microarray analysis  
RNA was purified from whole P15 tumors of 4 Math1-Cre;SmoM2 and 4 Math1-
Cre;SmoM2;Bcl-xLcKO mice according to manufacturer’s protocol (RNeasy Mini Kit, 
#74104, QIAGEN). The quality and quantity of RNA were determined by 
spectrophotometry, capillary gel electrophoresis, and NanoDrop. Samples were 
prepared using the Ambion® WT Expression Kit for High-Throughput Robotics 
(#4440537) and the Affymetrix® HT WT Terminal Labeling and Controls Kit (#901647). 
We quantified transcripts using the Affymetrix Mouse Gene 2.1 ST 24-Arrays (#902140, 
Affymetrix) and scanned with the Affymetrix GeneChip Scanner 3000 7G Plus. Data 
were processed using the Partek Genomics Suite 6.6 standard workflow for expression 





Single-cell RNA-seq data comparisons 
We manually compared genes with the lowest p-value from our microarray study 
to our database of single-cell RNA-seq data from P15 M1-Cre;SmoM2 mice146. These 
data include tumors from mice that have been injected with vismodegib or saline 
controls and allow for visualization of gene expression according to cell type. Our 
single-cell interface is freely available at http://gershon-lab.med.unc.edu/single-cell/. 
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3.6 Figures and Legends  
Figure 1. Targeting Bcl-xL in SHH-driven medulloblastoma mouse model                   
(A) H&E stained sagittal brain sections from P15 Math1-Cre;SmoM2;Bcl-xLcKO and 
Math1-Cre;SmoM2 mice. Focal necrosis indicated by the black arrow and areas of 
acellularity are indicated by black asterisks. Conditional deletion of Bcl2l1 was verified 
by IHC for BCL-xL in representative sagittal sections from the indicated genotypes, 
counterstained blue with hematoxylin. Size markers indicate 1mm in low magnification 
images and 500 µm in high magnification images. (B) Kaplan Meier curve comparing 
survival of Math1-Cre;SmoM2 (n=12), Math1-Cre;SmoM2;Bcl-xLHET (n=19) and Math1-
Cre;SmoM2;Bcl-xLcKO (n=18) mice, show significantly longer survival in Math1-











Figure 2. Bcl-xL deleted tumor cells persist despite increased apoptosis.             
(A) Representative cC3 IHC in sagittal sections from P12 and P20 Math1-
Cre;SmoM2;Bcl-xLHET  and Math1-Cre;SmoM2;Bcl-xLcKO mice, with quantification (B) of 
%cC3+ cells in the tumor from indicated genotypes, demonstrate increased apoptosis at 
P12 in Math1-Cre;SmoM2;Bcl-xLcKO tumors. (C) Representative PCNA/cC3 IF sections 
from P12 Math1-Cre;SmoM2;Bcl-xLHET  and Math1-Cre;SmoM2;Bcl-xLcKO with (D) 
quantification of the %cC3+ cells in that are PCNA+ and PCNA- , show that cell death is 
higher in the PCNA- population of Math1-Cre;SmoM2;Bcl-xLcKO. (E) Representative 
BCL-xL IHC at P12 and P20 show that tumor cells with Bcl-xL deletion continue to 
populate Math1-Cre;SmoM2;Bcl-xLcKO tumors. Size markers indicate 1mm in low 
magnification images and 500 µm in high magnification images. Nuclei are 
counterstained with hematoxylin in IHC images and with DAPI in IF images. P values 






Figure 3. Bcl-xL deleted tumors up-regulate proliferative markers                           
(A) Representative pHH3 IHC in sagittal tumor sections from P12 and P20 Math1-
Cre;SmoM2;Bcl-xLHET  and Math1-Cre;SmoM2;Bcl-xLcKO mice, with quantification (B) of 
%pHH3+ cells in the tumor from indicated genotypes, demonstrate increased mitoses in 
Math1-Cre;SmoM2;Bcl-xLcKO tumors. (C) Representative dot plots or pRB fluorescence 
intensity (FI) versus DNA content, measured by flow cytometry, in P12 Math1-
Cre;SmoM2;Bcl-xLcKO and Math1-Cre;SmoM2 control tumors show higher pRB 
expression in G1 with Bcl-xL deletion. Quantification (D) of pRB+ cells in dissociated 
tumors from (C) in the indicated genotypes. (E) Representative sagittal sections of pRB 
IF from P20 Math1-Cre;SmoM2;Bcl-xLHET and Math1-Cre;SmoM2;Bcl-xLcKO mice, with 
quantification (F) of %pRB+ cells in the tumor from indicated genotypes, show increased 
pRB expression in Math1-Cre;SmoM2;Bcl-xLcKO tumors. Size markers indicate 1mm in 
low magnification images and 500 µm in high magnification images. Nuclei are 
counterstained with hematoxylin in IHC images and with DAPI in IF images. P values 






Figure 4. MCL-1 is regulated by SHH in medulloblastoma mouse model               
(A) Representative pRB IF in sagittal tumor sections from P12 Math1-Cre;SmoM2 mice, 
injected at P10 and P11 with pOX-vismodegib or equal volume saline show decrease 
pRB with blockage of SHH signaling. (B) Representative dot plots of pRB fluorescence 
intensity (FI) versus DNA content, measured by flow cytometry, in P12 Math1-
Cre;SmoM2 mice show depletion of pRB+ cells in G0/G1 and S-G2M with Vismodegib 
treatment. (C) Representative histograms of pRB FI measured by flow cytometry 
demonstrate the cut-off used to quantify % pRB+ and pRB- dissociated tumor cells as 
shown in (D) for control and Vismodegib treated Math1-Cre;SmoM2 mice at P12. (E) 
Representative dot plots of MCL-1 FI versus DNA content, measured by flow cytometry 
and stratified into G0/G1, S and G2/M fractions show S-G2M tumor cells are consistently 
MCL-1+. Representative histograms in (F) show cut-off used to quantify % MCL-1+ and 
MCL-1- dissociated tumor cells (G) and demonstrate that MCL-1 protein abundance is 
regulated by SHH signaling in tumors of Math1-Cre;SmoM2 mice. (H) Representative 
histograms of preliminary data P12 Math1-Cre;SmoM2;Bcl-xLHET and Math1-
Cre;SmoM2;Bcl-xLcKO dissociated tumors show increased  MCL-1 protein abundance 
with deletion of Bcl-xL. Size markers indicate 1mm in low magnification images and 500 
µm in high magnification images. Nuclei are counterstained with DAPI in IF images. P 







Figure 5. Differential gene expression in Math1-Cre;SmoM2;Bcl-xLcKO show up 
regulated proliferation markers. (A) Volcano plot demonstrating genes with Log2 fold 
change (FC) ≥1.5 and FDR corrected p-value ≤1x10-3 in P15 Math-1Cre;Smom2;Bcl-
xLcKO (n=4) versus Math-1Cre;Smom2 control (n=4) tumors. Black lines represent 
significance cut-offs, with down-regulated genes in red and up-regulated genes in 
green. (B) Representative t-SNE projection of tumor cells from 5 Math1-Cre;SmoM2 
tumors, generated with Gershon Lab Single-Cell interface, color-coded for the 
expression of indicated markers. Nodes A-D correspond to increasingly differentiated 
cells, and show Cdca4 and Cdk2 expression are highest in proliferative tumor cells 
(Nodes A and B). (C) Representative dot plots show upregulation of Cdca4 and Cdk2 in 
Math1-Cre;SmoM2;Bcl-xLcKO tumors. (D) Representative t-SNE projections of Math1-
Cre;SmoM2 tumors treated either with saline (no drug), or vismodegib show Cd44+ 





Figure 6. Math1-Cre;SmoM2;Bcl-xLcKO tumors show increased microglia markers 
and TAMs. (A) Representative Iba1 IF sections from P12 and P20 Math1-
Cre;SmoM2;Bcl-xLHET  and Math1-Cre;SmoM2;Bcl-xLcKO tumors with (B) quantification 
of the %Iba1+ cells, show increased presence of TAMs in Bcl-xL deleted tumors. Size 
markers indicate 1mm in low magnification images and 500 µm in high magnification 
images. Nuclei are counterstained with DAPI. P values determined by two-tailed 







Table 3.1 Top differentially expressed genes of P15 Math1-Cre;SmoM2;Bcl-xLcKO 
vs. Math1-Cre;SmoM2 tumors 
Gene FDR* Log2(FC) Gene FDR* Log2(FC) Gene FDR* Log2(FC) 
Tnf 9.83E-07 2.11 Tec 9.52E-05 1.73 Slc25a32 2.62E-04 1.55 
Ttr 2.11E-06 -35.19 Abca8a 9.54E-05 1.73 Tubd1 2.65E-04 1.82 
Cdca4 5.95E-06 1.67 Gdf11 9.99E-05 1.64 Stab1 2.68E-04 2.18 
Stom 1.21E-05 1.87 Msrb3 1.01E-04 1.62 Mfsd7c 2.71E-04 1.56 
Cyb5d2 2.38E-05 1.52 Zfp964 1.10E-04 1.75 Gm19609 2.73E-04 -1.61 
Ccl28 2.46E-05 2.11 C130074G19Rik 1.32E-04 1.52 Tfpi 2.73E-04 1.77 
Ptpn6 2.54E-05 1.98 Gm4981 1.43E-04 -1.59 Ptprc 2.74E-04 2.28 
Creld2 2.61E-05 1.64 C1qtnf6 1.51E-04 1.63 Cd44 2.75E-04 1.78 
Anxa3 2.74E-05 2.61 Gm1943 1.52E-04 3.52 Tnfaip2 2.77E-04 1.95 
Tbxas1 2.87E-05 1.53 Tmem106a 1.60E-04 1.77 Rasgrf2 2.78E-04 -2.06 
Sostdc1 2.90E-05 -2.13 Rcsd1 1.69E-04 1.56 Scarna3a 2.81E-04 -1.97 
Cdh5 3.01E-05 1.87 4833423F13Rik 1.69E-04 -1.76 Rps19bp1 2.81E-04 1.52 
Ctla2a 3.03E-05 2.32 Thbd 1.73E-04 1.95 Il10rb 2.82E-04 2.43 
Bcl2l1 3.05E-05 -2.56 Car5b 1.78E-04 2.91 Gna15 2.85E-04 1.97 
Plin2 3.38E-05 1.71 Sox7 1.80E-04 2.04 Aoah 2.89E-04 2.53 
Cntn2 3.62E-05 -2.29 Ahcy 1.82E-04 4.98 Lcp1 2.92E-04 1.73 
Rundc1 4.19E-05 1.56 Nr1h3 1.83E-04 1.65 Cxcl16 2.96E-04 2.22 
Ms4a4a 4.58E-05 3.11 Tas2r143 1.85E-04 -1.76 Rps6ka4 2.96E-04 1.56 
Cp 4.81E-05 3.11 Atf3 1.99E-04 1.89 Gtse1 2.96E-04 1.86 
Nid1 5.42E-05 2.28 Tlr9 2.00E-04 1.52 Col6a1 3.01E-04 2.36 
Mylip 6.17E-05 1.94 Cox5b 2.07E-04 2.23 Myl9 3.03E-04 1.70 
Xdh 6.65E-05 1.74 Tnfaip8l2 2.29E-04 2.33 2310075C17Rik 3.05E-04 -2.26 
Pla2g4a 7.53E-05 1.60 Cdca5 2.41E-04 1.99 Stard5 3.15E-04 1.55 
Crb1 8.11E-05 -1.57 As3mt 2.52E-04 1.91 1700003M02Rik 3.26E-04 -1.91 
Pik3cg 8.21E-05 1.83 Irf8 2.53E-04 1.92 Rasgef1b 3.28E-04 2.65 
Hpse 8.36E-05 3.06 Igsf6 2.57E-04 2.88 Lilrb4 3.28E-04 5.24 
Snord17 9.25E-05 -2.15 Dusp5 2.60E-04 -1.88 Ms4a14 3.29E-04 2.31 
Top 81 (of 188) differentially expressed genes defined as |Log2(FC)|>1.5 and FDR 
p≤0.001 from microarray. *Genes are ordered by FDR. Genes in bold font are 
highlighted in volcano plot for Fig. 5.  
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Table 3.2 Annotated differential gene expression of P15 Math1-Cre;SmoM2;Bcl-
xLcKO vs. Math1-Cre;SmoM2 tumors 
Selection of top differentially expressed genes defined as |Log2(FC)|>1.5 and FDR 
p≤0.001 from microarray. *Genes are ordered by FDR. Genes in bold font are 
highlighted in volcano plot for Fig. 5. ±Notes generated from comparing differentially 
expressed gene list to Gershon Lab single-cell database to determine cell population 
with highest expression. 
  
Gene  Gene Name FDR* Log2(FC) Notes± 
Tnf Tumor Necrosis Factor 9.82E-07 2.10 microglial marker 
Ttr Transthyretin 2.11E-06 -35.19 differentiation marker  
Cdca4 
Cell Division Cycle 
Associated 4 5.95E-06 1.58 proliferation marker 
Stom Stomatin 1.21E-05 1.87 microglial marker 
Cyb5d2 
Cytochrome B5 Domain 
Containing 2 2.38E-05 1.51 role unclear  
Ccl28 
C-C Motif Chemokine 




Receptor Type 6 2.54E-05 1.97 microglial marker 
Creld2 
Cysteine Rich With EGF 
Like Domains 2 2.61E-05 1.63 role unclear  
Anxa3 Annexin A3 2.74E-05 2.60 microglial marker 
Tbxas1 
Thromboxane A 
Synthase 1 2.87E-05 1.52 microglial marker 
Sostdc1 
Sclerostin Domain 
Containing 1 2.90E-05 -2.13 unable to validate 
Cdh5 Cadherin 5 3.01E-05 1.86 endothelial cell marker 
Ctla2a 
Cytotoxic T lymphocyte-
Associated Protein 2 
alpha 3.03E-05 2.32 microglial marker 
Bcl2l1 BCL2 Like 1 3.05E-05 -2.55 BCL-xL 
Plin2 Perilipin 2 3.38E-05 1.71 microglial marker 









CHAPTER FOUR: SUMMARY AND FUTURE DIRECTIONS 
4.1 Apoptotic regulation in the developing cerebellum  
Summary  
The work presented in Chapter 2 of this dissertation provides new information on 
apoptotic regulation in the developing central nervous system. My findings show a 
hierarchical need for anti-apoptotic proteins in postnatal cerebellar neurogenesis that 
differs from embryonic brain development. Traditionally MCL-1 has been shown to be a 
critical pro-survival protein in embryonic NPCs109,110, while BCL-xL is known to protect 
post-mitotic cortical neurons from cell death106. Using mice with conditional deletion of 
multiple BCL-2 family proteins (Figure 1), I show proliferating CGNPs uniquely require 
BCL-xL for survival, and that MCL-1 is not required for cerebellar development but can 
compensate for loss of BCL-xL. Further, my data show that anti-apoptotic MCL-1 may 
link apoptosis to proliferation through inhibition of SUFU. The major findings and 
conclusions are summarized below:  
1. Conditional deletion of Bcl-xL in CGNPs causes cerebellar hypoplasia by 
increasing spontaneous CGNP apoptosis, but also prolongs the duration of 
CGNP proliferation in the external granule layer.  
2. Bcl-xL deletion increases apoptosis in proliferating progenitors and newly 
differentiated cells, with the latter being most vulnerable to apoptosis.  
3. Co-deletion of Bax and Bcl-xL in CGNPs rescues the phenotype of Bcl-xL 
deletion alone, restoring apoptosis and proliferation to normal.  
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4. In mice with Bcl-xL deletion, forcing cell cycle exit by blocking SHH signaling 
reduces the total number of cells in the external granule layer, linking BCL-xL 
dependency to proliferation status.  
5. MCL-1 is present during all phases of the CGNP cell cycle, but highest in S-
G2M cells and MCL-1 protein abundance increases when BCL-xL is deleted.  
6. Deletion of Mcl-1 in CGNPs produces no phenotype. However, co-deletion of 
Mcl-1 and Bcl-xL restricts apoptosis to proliferating cells, and reduces the 
number of mature neurons of the internal granule layer, showing MCL-1 is 
required for survival by proliferating cells only when BCL-xL is absent.  
7. The increase of MCL-1 protein abundance in Bcl-xL deleted CGNPs 
correlates with an increased expression of downstream SHH targets and may 
be through MCL-1:SUFU interaction.  
Future Directions 
My data suggest that MCL-1 maintains proliferating CGNPs when Bcl-xL is 
deleted, and that MCL-1 abundance correlates with increased SHH signaling. A recent 
study showed in vitro that cytosolic BCL-2 proteins including MCL-1 promote SUFU 
turnover, bind SUFU inhibiting interaction with GLI and induce expression of GLI target 
genes124. I directly tested the hypothesis that MCL-1 binds to SUFU in CGNPs of P7 
Bcl-xLcKO mice through western blot and immunoprecipitation (IP) experiments (Figure 
2A,B). My preliminary data show that Bcl-xLcKO does not change the abundance of 
SUFU (Figure 2A), but markedly alters the binding of SUFU to MCL-1 (Figure 2B). In 
contrast, ionizing radiation, which my lab has found to increase MCL-1 abundance, 
does not increase SUFU:MCL-1 interaction (Figure 2B). These contrasting findings 
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demonstrate that the increased MCL-1:SUFU interaction is a specific effect of Bcl-xL 
deletion, rather than a non-specific effect of increased MCL-1 abundance. My 
preliminary results confirm that MCL-1 only binds SUFU in Bcl-xLcKO cerebella providing 
a mechanism for increased proliferation of Bcl-xLcKO CGNPs (Figure 3). These data 
establish a new pro-survival role for MCL-1 through increasing SHH signaling in the 
absence of BCL-xL, and will be further validated through replicate experiments. 
 The question remains if MCL-1 substitutes for BCL-xL by binding to active BAX 
in Bcl-xLcKO CGNPs. One method for testing this hypothesis would be to IP active BAX 
in Bcl-xLcKO CGNPs and western blot for MCL-1. Additionally, it is unknown if BCL-xL 
binds SUFU in WT CGNPs under normal developmental conditions promoting SHH-
driven proliferation. This could be tested using a BCL-xL IP in WT CGNPs then western 
blotting for SUFU. All together, these future experiments will further clarify the role of 
BCL-2 proteins in apoptosis and SHH-dependent proliferation in the developing 
cerebellum.   
4.2 Targeting intrinsic apoptosis in medulloblastoma  
Summary  
The work presented in Chapter 3 of this dissertation shows how conserved 
developmental apoptotic mechanisms contribute to medulloblastoma tumorigenesis and 
recurrence. The efficacy of current MB therapy relies on the intrinsic apoptosis 
pathway142. I directly targeted activation of the intrinsic pathway of using conditional 
deletion of Bcl-xL in a mouse model that recapitulates numerous aspects of human 
SHH-driven medulloblastoma. My results in MB showed a pattern similar to disruption of 
Bcl-xLcKO cerebella, with an initial increase in spontaneous apoptosis and heightened 
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proliferation. The increased apoptosis, however, waned over time, which may support 
recurrence. My results also show the potential therapeutic effect of directly activating 
the intrinsic apoptotic pathway and suggest a therapeutic approach combining SHH 
signaling inhibition. The major findings and conclusions are summarized below: 
1. Conditional deletion of Bcl-xL in SHH-MB shows histological indications of 
focal tumor necrosis and significantly increases survival in mice.  
2. All Bcl-xL deleted tumors eventually progress, causing mice to die by age 
87d, suggesting development of resistance to BCL-xL disruption that was 
confirmed by persistence of Bcl-xL deleted tumor cells in IHC sections.    
3. Overall apoptosis increases in Bcl-xL deleted tumors at P12, and like CGNPs 
both proliferating and differentiating cells die, although differentiated MB cells 
are more frequently affected.  
4. Bcl-xL deleted tumors, like CGNPs, also increase proliferation and this 
increase contributes to tumor recurrence. 
5.  Blocking SHH signaling with vismodegib decreases MCL-1 protein 
abundance in MB with intact Bcl-xL and preliminary data show MCL-1 is 
increased in Bcl-xL deleted MB cells, similar to CGNPs. Thus, MCL-1 may 
have a similar pro-survival function in Bcl-xL deleted tumors by potentiating 
SHH signaling through interacting with SUFU.  
6.  Differential gene expression analysis confirms up-regulation of proliferation in 
Bcl-xL deleted tumors, and shows increased expression of macrophage 
associated genes which may ultimately have an anti-tumor effect.  
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Clinical Relevance 
Developing low-toxicity, subtype-specific treatments of medulloblastoma may 
revolutionize patient care and increase overall survival. My studies utilized a relevant 
pre-clinical model of SHH-driven medulloblastoma to determine in vivo effects of directly 
activating the intrinsic apoptosis pathway.  While my studies use genetic deletion to 
deplete BCL-xL with high specificity in tumor cells of the Math1 lineage, the protein may 
also be targeted systemically using BH3-mimetics and other pharmacologic 
inhibitors160,161. The toxicity and brain penetration of these agents is currently under 
study162,163. However, specific brain-penetrant agents have been safe for clinical 
trials163. Additionally, we have collaborated with the UNC TransNanoForm core to 
formulate a poly(2-oxazoline) micelle packaged version ABT-263, a BH-3 mimetic 
currently in multiple clinical trials for chronic lymphocytic leukemia, small-cell lung 
cancer and other solid tumors164–166.  
I propose that combined targeting of BCL-xL and SHH signaling may lead to 
greater anti-tumor effects than either intervention alone. The BCL-xL dependence of 
CGNPs and MB cells as they exit the cell cycle, suggests that Vismo may sensitize 
medulloblastoma cells to Bcl-xL deletion by impeding cell cycle re-entry. If SMO 
inhibition increases the sensitivity of medulloblastoma cells to Bcl-xL disruption, 
combined targeting of SMO and Bcl-xL may trigger widespread apoptosis and eliminate 
the tumor before resistant clones can emerge. Future studies to determine the efficacy 
of combination treatment will be outlined below.  
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Future Directions 
My data suggests that inhibition of SHH signaling in combination with disruption 
of BCL-xL may be effective to treat SHH-MB. To directly test this hypothesis I am 
currently conducting a survival study with long term vismodegib administration in Math1-
Cre;SmoM2;Bcl-xLHET and Math1-Cre;SmoM2;Bcl-xLcKO mice. Mice are injected with 
Vismo once daily from P10-P12, and then every other day until P35. If Vismo treated 
Math1-Cre;SmoM2;Bcl-xLcKO mice show a significant increase in survival, future studies 
will be conducted to test the efficacy of combining ABT-263 and Vismo in mice with Bcl-
xL intact tumors. Alternatively, if there is no survival benefit combining SHH and BCL-xL 
inhibition, future studies will determine if BCL-xL disruption increases the efficacy of 
conventional chemotherapy and radiation therapy.   
Given my data showing MCL-1 is present in proliferating MB cells and decreases 
with SHH inhibition, the question remains if MCL-1 contributes to increased proliferation 
of tumor cells as seen in CGNPs. Future studies will confirm my preliminary data that 
MCL-1 is increased in Bcl-xL deleted tumors using flow cytometry and western blot 
comparing Math1-Cre;SmoM2;Bcl-xLHET and Math1-Cre;SmoM2;Bcl-xLcKO tumors . If 
MCL-1 abundance is increased, an IP experiment will be conducted to confirm MCL-
1:SUFU interaction, which would suggest MCL-1 contributes to proliferation and thus 
tumor recurrence in Bcl-xL deleted tumors. Additionally, future studies will determine if 
co-deletion of Bcl-xL and Mcl-1 in our model of SHH-MB, which we are currently 
generating, increases overall survival compared to tumors with only Bcl-xL deletion. 
Together, the data from these proposed experiments would determine if MCL-1 
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promotes tumor cell survival in the absence of BCL-xL, and if targeting both BCL-xL and 
MCL-1 would limit tumor recurrence.  
 My data also show an increase in expression of macrophage associated genes 
that correlated with a greater number of TAMs in Bcl-xL deleted tumors. The 
contribution of TAMs to medulloblastoma progression is in the infant stages of 
investigation. While TAMs have been reported as a poor prognostic marker that 
promote tumor progression and metastasis in multiple cancers (e.g., thyroid cancer, 
hepatocellular carcinoma, and glioblastoma)167–170, a recent report indicates an anti-
tumor role for TAMs in SHH-MB154.  In human patients with SHH-MB this study showed 
a significantly worse prognosis correlated with decreased expression of the pan-
macrophage gene AIF1 (IBA1). This study also used in vivo and ex vivo murine SHH-
MB models to provide a mechanistic understanding of anti-tumor TAM effects. They 
propose tumor cells activate microglia, which in turn recruit circulating monocytes to the 
tumor tissue through release of the cytokine CCL2. Following recruitment, monocytes 
differentiate and promote tumor cell death.  
I propose the following pilot experiment using clodronate liposomes to reduce 
macrophage number and determine if a similar anti-tumor mechanism exists in Bcl-xL-
deleted tumors. In mice, repeated administration of clodronate liposomes induces 
apoptosis of circulating phagocytic monocytes171. To determine initial efficacy in our 
SHH-MB model, Math1-Cre;SmoM2;Bcl-xLHET and Math1-Cre;SmoM2;Bcl-xLcKO mice 
will be injected with clodronate liposomes once daily on P10 and P11 and sacrificed 
24hrs later at P12. IF analysis of IBA1+ cells in tumor sections will be used to confirm 
reduction of infiltrating macrophages and can be compared to previously generated data 
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of untreated tumors from the same genotypes (Chapter 3, Figure 6).  If macrophages 
are reduced, follow up survival studies using long-term administration of clodronate 
liposomes in Bcl-xL deleted tumor mice would show if TAMs derived from monocytes 
have an anti-tumor effect.  
Lastly, our lab is currently analyzing single-cell RNA sequencing data of Math1-
Cre;SmoM2;Bcl-xLHET and Math1-Cre;SmoM2;Bcl-xLcKO tumors at P12 and P20 that I 
generated (Figure 4). Using 3 biological replicates in each condition, we isolated 33,538 
individual cells and sequenced 20,157 total genes. Analysis of this data will resolve how 
transcriptional changes within specific tumor cell subpopulations (e.g., proliferating, 
differentiating, glial, stromal, etc.) change overtime and with the deletion of Bcl-xL. This 
data will also allow us to define novel cell types that emerge in Math1-Cre;SmoM2;Bcl-
xLcKO tumors which may contribute to recurrence.  
Overall my findings in Bcl-xL deleted MB tumors lay the foundation for many 
interesting avenues of future research. These outlined studies will further elucidate if 
dual targeting of BCL-xL and SHH inhibition prevent tumor progression, if MCL-1 
potentiates SHH signaling in the absence of BCL-xL, and if TAMs play an anti-tumor 
role that contributes to increased survival in mice with Bcl-xL deleted tumors. These 
findings are critical for understanding implications of directly activating the intrinsic 




4.3 Figures and Legends  
Figure 1. Bcl-xLcKO, Bcl-xL;BaxdKO, and Bcl-xL;Mcl-1dKO phenotypes                      
P7 Bcl-xLcKO cerebella display apoptosis in both proliferating and newly differentiated 
cells, illustrating the importance of BCL-xL for CGNP survival during multiple 
developmental stages. Apoptosis is restored to normal levels in Bcl-xL;BaxdKO cerebella 
similar to WT, suggesting apoptosis is BAX dependent. Lastly, apoptosis only occurs in 
proliferating CGNPs of Bcl-xL;Mcl-1dKO cerebella resulting in a lack of differentiated cells 









Figure 2. MCL-1 binds to SUFU to promote proliferation in Bcl-xLcKOs.                  
(A) Representative western blots comparing the abundance of SUFU protein in lysates 
of whole cerebella of P7 Bcl-xLcKO and WT control mice, with quantification of SUFU 
abundance normalized to -actin show overall SUFU levels do not significantly differ in 
Bcl-xLcKO cerebella compared to WT controls. Dots indicate data from individual 
replicate mice and horizontal bars with error bars indicate the mean +/-SEM. P values 
determined by two-tailed Student’s t-test. (B) Representative IP using MCL-1 antibody 
on lysates of whole cerebella of WT, irradiated (xRT) WT, and Bcl-xLcKO show increased 







Figure 3.  Proposed mechanism for MCL-1 and SUFU in Bcl-xLcKOs.                              
In the absence of SHH ligand, SUFU inhibits GLI2, preventing translocation to the 
nucleus. SHH binding in CGNPs releases SUFU inhibition through activation of GLI2. 
GLI2 moves to the nucleus and acts as a transcription factor to promote expression of 
genes involved in cellular proliferation. The question remains if BCL-xL is important for 
inhibiting SUFU in WT CGNPs. In CGNPs of Bcl-xLcKO mice, MCL-1 abundance 
increases in the absence of BCL-xL. MCL-1 directly promotes SHH signal transduction 
by binding SUFU, further releasing GLI2 and allowing for increased potentiation of 
GLI2-dependent downstream effects. This results in increased duration of CGNP 







Figure 4.  Preliminary single cell RNA-seq analysis                                                        
Unsupervised analysis of preliminary data using UMAP (uniform manifold approximation 
and projection) embedding of the top 16 PCs (principal components) derived from the 
top 3,000 most variably expressed genes in the total cell population. Segregated by age 
(P12, P20) and colored by genotype (Math1-Cre;SmoM2;Bcl-xLHET and Math1-
Cre;SmoM2;Bcl-xLcKO). Black arrow indicates axis of differentiation determined by 
expression of ATOH1 (proliferation) and MEG3 (differentiation) in total cells. Arrow head 
points towards higher MEG3 expression and is the same for each genotype. Analysis 
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